Propanc Biopharma (PPCBD) 10-Q 15 May 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Mar. 31, 2023	May 12, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--06-30
Entity File Number	000-54878
Entity Registrant Name	PROPANC BIOPHARMA, INC.
Entity Central Index Key	0001517681
Entity Tax Identification Number	33-0662986
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell, VIC
Entity Address, Country	AU
Entity Address, Postal Zip Code	3124
City Area Code	61-03
Local Phone Number	9882-0780
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,288,404,722

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Jun. 30, 2022
CURRENT ASSETS:
Cash	$ 93,241	$ 4,067
GST tax receivable	3,334	2,342
Prepaid expenses and other current assets		8,621
TOTAL CURRENT ASSETS	96,575	15,030
Security deposit - related party	2,009	2,075
Operating lease right-of-use assets, net - related party	44,524	62,523
Property and equipment, net	634	2,023
TOTAL ASSETS	143,742	81,651
CURRENT LIABILITIES:
Accounts payable	918,195	943,023
Accrued expenses and other payables	687,454	466,115
Accrued interest	56,661	57,822
Loan payable	65,280
Convertible notes, net of discounts and including put premiums	519,718	926,438
Operating lease liability - related party, current portion	21,185	20,605
Embedded conversion option liabilities	132,501	151,262
Due to former director - related party	$ 29,777	$ 30,746
Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration]	Related Party [Member]	Related Party [Member]
Loan from former director - related party	$ 49,558	$ 51,171
Employee benefit liability	579,888	415,799
TOTAL CURRENT LIABILITIES	3,060,217	3,062,981
NON-CURRENT LIABILITIES:
Operating lease liability - long-term portion - related party	24,939	42,319
TOTAL NON-CURRENT LIABILITIES	24,939	42,319
TOTAL LIABILITIES	3,085,156	3,105,300
Commitments and Contingencies (See Note 8)
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; 10,000,000,000 shares authorized;  2,621,297,786 and 220,350,921 shares issued and outstanding as of  March 31, 2023 and June 30, 2022, respectively	2,621,298	220,351
Common stock issuable (4,434 and 19,597,024 shares as of March 31, 2023 and June 30, 2022, respectively)	4	19,597
Additional paid-in capital	57,068,986	57,124,982
Subscription receivable		(23,758)
Accumulated other comprehensive income	1,293,747	1,234,549
Accumulated deficit	(63,878,972)	(61,557,893)
Treasury stock (1 share)	(46,477)	(46,477)
TOTAL STOCKHOLDERS’ DEFICIT	(2,941,414)	(3,023,649)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	143,742	81,651
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock value		5,000
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Jun. 30, 2022
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	2,621,297,786	220,350,921
Common stock, shares outstanding	2,621,297,786	220,350,921
Common stock, shares issuable	4,434	19,597,024
Treasury stock, shares	1	1
Series A Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	0	500,000
Preferred stock, shares outstanding	0	500,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1
Treasury stock, shares	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	311,824	443,629	1,302,576	1,221,533
Occupancy expenses - related party	8,365	8,157	22,244	22,443
Research and development	66,020	50,395	242,223	147,702
TOTAL OPERATING EXPENSES	386,209	502,181	1,567,043	1,391,678
LOSS FROM OPERATIONS	(386,209)	(502,181)	(1,567,043)	(1,391,678)
OTHER INCOME (EXPENSE)
Interest expense	(157,208)	(167,375)	(418,579)	(455,133)
Interest income	8		27
Change in fair value of derivative liabilities	(238,367)	165,365	(110,859)	(2,392)
Gain from settlement of accounts payable			17,499
Gain on extinguishment of debt, net	(10,724)		32,186
Foreign currency transaction gain (loss)	(19,025)	41,717	3,210	40,631
TOTAL OTHER EXPENSE, NET	(425,316)	39,707	(476,516)	(416,894)
LOSS BEFORE TAXES	(811,525)	(462,474)	(2,043,559)	(1,808,572)
Tax benefit	1,716	(213)	131,037	55,250
NET LOSS	(809,809)	(462,687)	(1,912,522)	(1,753,322)
Deemed Dividend		(237,389)	(408,557)	(445,631)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (809,809)	$ (700,076)	$ (2,321,079)	$ (2,198,953)
BASIC AND DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ 0	$ (0.01)	$ 0	$ (0.05)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	1,924,073,522	66,353,881	1,115,848,071	47,561,123
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	$ 40,614	$ (55,096)	$ 59,198	$ 1,400
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	40,614	(55,096)	59,198	1,400
TOTAL COMPREHENSIVE LOSS	$ (769,195)	$ (755,172)	$ (2,261,881)	$ (2,197,553)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common [Member]	Total
Beginning balance, value at Jun. 30, 2021	$ 5,000		$ 14,056		$ 54,074,110		$ (58,199,466)	$ 1,085,204	$ (46,477)	$ (3,067,573)
Beginning balance, shares at Jun. 30, 2021	500,000	1	14,055,393	59
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 9,445		190,741					200,186
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			9,445,009
Issuance of common stock for services and accrued expenses			$ 17,934		563,927					581,861
Issuance of common stock for services and accrued expenses, shares			17,934,379
Issuance of common stock for exercise of warrants			$ 7	$ 2	374,991	(100,000)				275,000
Issuance of common stock for exercise of warrants, shares			6,875	2,500
Issuance of common stock for alternate cashless exercise of warrants			$ 2,400	$ 2,000	(4,400)
Issuance of common stock for alternate cashless exercise of warrants, shares			2,399,988	1,999,990
Reclassification of put premium upon debt conversion					109,643					109,643
Stock based compensation in connection with stock option grants					20,718					20,718
Foreign currency translation loss								64,193		64,193
Deemed dividend upon alternate cashless exercise of warrants					114,844		(114,844)
Net loss							(490,658)			(490,658)
Ending balance, shares at Sep. 30, 2021	500,000	1	43,841,644	2,002,549
Ending balance, value at Sep. 30, 2021	$ 5,000		$ 43,842	$ 2,002	55,444,574	(100,000)	(58,804,968)	1,149,397	(46,477)	(2,306,630)
Beginning balance, value at Jun. 30, 2021	$ 5,000		$ 14,056		54,074,110		(58,199,466)	1,085,204	(46,477)	(3,067,573)
Beginning balance, shares at Jun. 30, 2021	500,000	1	14,055,393	59
Foreign currency translation loss										1,400
Net loss										(1,753,322)
Reclassification of put premium upon debt conversion										227,150
Ending balance, shares at Mar. 31, 2022	500,000		85,030,026	1,149,635
Ending balance, value at Mar. 31, 2022	$ 5,000		$ 85,030	$ 1,149	56,319,693		(60,398,419)	1,086,604	(46,477)	(2,947,420)
Beginning balance, value at Sep. 30, 2021	$ 5,000		$ 43,842	$ 2,002	55,444,574	(100,000)	(58,804,968)	1,149,397	(46,477)	(2,306,630)
Beginning balance, shares at Sep. 30, 2021	500,000	1	43,841,644	2,002,549
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest				$ 1,818			24,908			26,726
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares				1,818,097
Issuance of common stock for exercise of warrants			$ 2	$ (2)		100,000				100,000
Issuance of common stock for exercise of warrants, shares			2,500	(2,500)
Issuance of common stock for alternate cashless exercise of warrants			$ 6,400	$ (2,000)	(4,400)
Issuance of common stock for alternate cashless exercise of warrants, shares				(1,999,990)
Stock based compensation in connection with stock option grants					20,718					20,718
Foreign currency translation loss								(7,697)		(7,697)
Deemed dividend upon alternate cashless exercise of warrants					93,398		(93,398)
Net loss							(799,977)			(799,977)
Issuance of common stock for deferred offering cost			1,000		19,000					20,000
Issuance of common stock for deferred offering cost, shares			$ 1,000,000
Issuance of common stock for alternate cashless exercise of warrants, shares			6,399,968
Reclassification of put premium upon debt conversion					16,667					16,667
Ending balance, shares at Dec. 31, 2021		1	53,062,209	59
Ending balance, value at Dec. 31, 2021	5,000		$ 53,062		55,614,865		(59,698,343)	1,141,700	(46,477)	(2,930,193)
Issuance of common stock for exercise of warrants			$ 1	$ 1	99,998					100,000
Issuance of common stock for exercise of warrants, shares			1,250	1,250
Issuance of common stock for alternate cashless exercise of warrants			$ 9,800		(9,800)
Issuance of common stock for alternate cashless exercise of warrants, shares			9,799,951
Foreign currency translation loss								(55,096)		(55,096)
Deemed dividend upon alternate cashless exercise of warrants					237,389		(237,389)
Net loss							(462,687)			(462,687)
Reclassification of put premium upon debt conversion					100,840					100,840
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest				$ 19,226			170,742			189,968
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares				19,225,725
Issuance of common stock for services			$ 2,941	$ 1,148	84,941					89,030
Issuance of common stock for services, shares			2,940,891	1,148,326
Stock based compensation in connection with stock warrant grant					20,718					20,718
Ending balance, shares at Mar. 31, 2022	500,000		85,030,026	1,149,635
Ending balance, value at Mar. 31, 2022	$ 5,000		$ 85,030	$ 1,149	56,319,693		(60,398,419)	1,086,604	(46,477)	(2,947,420)
Beginning balance, value at Jun. 30, 2022	$ 5,000		$ 220,351	$ 19,597	57,124,982	(23,758)	(61,557,893)	1,234,549	(46,477)	(3,023,649)
Beginning balance, shares at Jun. 30, 2022	500,000	1	220,350,921	19,597,024
Issuance of common stock for exercise of warrants			$ 1	$ 1	99,998					100,000
Issuance of common stock for exercise of warrants, shares			1,250	1,250
Issuance of common stock for alternate cashless exercise of warrants			$ 158,399		(158,399)
Issuance of common stock for alternate cashless exercise of warrants, shares			158,399,208
Foreign currency translation loss								126,396		126,396
Deemed dividend upon alternate cashless exercise of warrants					389,235		(389,235)
Net loss							(617,295)			(617,295)
Reclassification of put premium upon debt conversion					133,646					133,646
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 264,493		192,446					456,939
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			264,492,661
Stock based compensation in connection with stock warrant grant					2,408					2,408
Issuance of common stock for cash			$ 14,337		10,374	23,758				48,469
Issuance of common stock for cash, shares			14,336,712
Issuance of common stock for issuable shares, shares			$ 19,597	$ (19,597)
Issuance of common stock for issuable shares, shares			19,596,965	(19,596,965)
Warrant grant for settlement of accounts payable					5,551					5,551
Ending balance, shares at Sep. 30, 2022	500,000	1	677,177,717	1,309
Ending balance, value at Sep. 30, 2022	$ 5,000		$ 677,178	$ 1	57,800,241		(62,564,423)	1,360,945	(46,477)	(2,767,535)
Beginning balance, value at Jun. 30, 2022	$ 5,000		$ 220,351	$ 19,597	57,124,982	(23,758)	(61,557,893)	1,234,549	(46,477)	(3,023,649)
Beginning balance, shares at Jun. 30, 2022	500,000	1	220,350,921	19,597,024
Foreign currency translation loss										59,198
Net loss										(1,912,522)
Reclassification of put premium upon debt conversion										351,992
Ending balance, shares at Mar. 31, 2023		1	2,621,297,786	4,434
Ending balance, value at Mar. 31, 2023			$ 2,621,298	$ 4	57,068,986		(63,878,972)	1,293,747	(46,477)	(2,941,414)
Beginning balance, value at Sep. 30, 2022	$ 5,000		$ 677,178	$ 1	57,800,241		(62,564,423)	1,360,945	(46,477)	(2,767,535)
Beginning balance, shares at Sep. 30, 2022	500,000	1	677,177,717	1,309
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 380,506		(214,815)					165,691
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			380,506,070
Issuance of common stock for exercise of warrants			$ 3		99,997					100,000
Issuance of common stock for exercise of warrants, shares			2,500
Issuance of common stock for alternate cashless exercise of warrants			$ 33,600		(33,600)
Issuance of common stock for alternate cashless exercise of warrants, shares			33,599,832
Foreign currency translation loss								(107,812)		(107,812)
Deemed dividend upon alternate cashless exercise of warrants					19,322		(19,322)
Net loss							(485,418)			(485,418)
Reclassification of put premium upon debt conversion					85,346					85,346
Issuance of common stock for services			$ 79,412		(22,601)					56,811
Issuance of common stock for services, shares			79,412,132
Issuance of common stock for issuable shares, shares			$ 1,250	(1,250)
Issuance of common stock for issuable shares			1	(1)
Issuance of common stock in connection with a note payable			$ 75,000		(37,500)					37,500
Issuance of common stock in connection with a note payable, shares			75,000,000
Ending balance, shares at Dec. 31, 2022	500,000	1	1,245,699,501	59
Ending balance, value at Dec. 31, 2022	$ 5,000		$ 1,245,700		57,696,390		(63,069,163)	1,253,133	(46,477)	(2,915,417)
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest				$ 1,375,598			(940,400)			435,198
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares				1,375,598,285
Issuance of common stock for exercise of warrants				$ 4	174,996					175,000
Issuance of common stock for exercise of warrants, shares			3,750	4,375
Foreign currency translation loss								40,614		40,614
Net loss							(809,809)			(809,809)
Reclassification of put premium upon debt conversion					133,000					133,000
Retirement of Series A Preferred Stock	(5,000)				5,000
Retirement of Series A Preferred Stock, shares	$ (500,000)
Ending balance, shares at Mar. 31, 2023		1	2,621,297,786	4,434
Ending balance, value at Mar. 31, 2023			$ 2,621,298	$ 4	$ 57,068,986		$ (63,878,972)	$ 1,293,747	$ (46,477)	$ (2,941,414)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,912,522)	$ (1,753,322)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance and amortization of common stock for services	56,811	222,452
Foreign currency transaction gain	(3,210)	(40,631)
Depreciation expense	1,345	1,503
Amortization of debt discounts	138,014	24,942
Amortization of right-of-use assets	16,029
Change in fair value of derivative liabilities	110,859	2,392
Gain on extinguishment of debt, net	(32,186)
Gain from settlement of accounts payable	(17,499)
Stock option, stock warrants and restricted stock expense	2,408	62,154
Non-cash interest expense		2,250
Accretion of put premium	232,674	380,962
Changes in Assets and Liabilities:
GST receivable	(1,065)	2,120
Prepaid expenses and other assets	8,348	(8,405)
Accounts payable	27,953	(34,319)
Employee benefit liability	177,198	23,816
Accrued expenses and other payables	236,034	43,285
Accrued interest	46,347	45,495
Operating lease liability	(14,816)
NET CASH USED IN OPERATING ACTIVITIES	(927,278)	(1,025,306)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	590,250	641,500
Proceeds from the sale of common stock	24,711
Collection of subscription receivable	23,758
Proceeds from the exercise of warrants	375,000	475,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,013,719	1,116,500
Effect of exchange rate changes on cash	2,733	40,436
NET INCREASE IN CASH	89,174	131,630
CASH AT BEGINNING OF PERIOD	4,067	2,255
CASH AT END OF PERIOD	93,241	133,885
Supplemental Disclosure of Cash Flow Information
Interest	1,544	1,485
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Common stock issued for offering cost applied against proceeds received		20,000
Reduction of put premium related to conversions of convertible notes	351,992	227,150
Conversion of convertible notes and accrued interest to common stock	823,206	414,630
Debt discounts related to derivative liability	93,668
Debt discounts related to common stock issued with a note payable	37,500
Warrant grant for settlement of accounts payable	5,551
Common stock issued for accrued services		448,440
Deemed dividend upon alternate cashless exercise of warrants	$ 408,557	$ 445,631

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of March 31, 2023, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 59 granted, allowed, or accepted patents and 17 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three and nine months ended March 31, 2023 and 2022 and cash flows for the three and nine months ended March 31, 2023 and 2022, and our consolidated financial position at March 31, 2023 have been made. The Company’s results of operations for the nine months ended March 31, 2023 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2023. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2022. The June 30, 2022 balance sheet is derived from those statements. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All intercompany balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through March 31, 2023. PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of March 31, 2023 and 2022, the Company recognized a cumulative exchange gain (loss) of approximately $ 556,000 15,600 As of March 31, 2023 and June 30, 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES March 31, 2023 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6697 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6794 0.7253 The change in Accumulated Other Comprehensive Income by component during the nine months ended March 31, 2023 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2022 $ 1,234,549 Unrealized foreign currency translation gain 59,198 Ending balance, March 31, 2023 $ 1,293,747 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 – Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7 Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as it is in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through March 31, 2023 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Employee Benefit Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of March 31, 2023, and June 30, 2022, the Company was owed $ 3,334 2,342 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $0.001 per share (“common stock”) at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 66,020 50,395 242,223 147,702 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. During each of the nine months ended March 31, 2023 and 2022, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 131,037 55,250 Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Legal Expenses All legal costs for litigation are charged to expense as incurred. Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operations and relate to the presentation of accrued interest separately on the consolidated balance sheet, of which $ 57,822 Basic and Diluted Net Loss Per Share of Common Stock Basic net loss per share of common stock is computed by dividing the net loss by the weighted average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants, restricted stock units and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per-share amounts for all periods presented are identical. Each holder of the notes and warrants has agreed to a 4.99 The Company’s CEO holds Series B Preferred Stock that, when combined, confers upon him a majority vote , including SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS March 31, 2023 March 31, 2022 (Unaudited) (Unaudited) Stock Options 59 59 Warrants with no designations 3,305,975 109,361 Series A Warrants as if converted at alternate cashless exercise prices 1,997,190,014 - Series B Warrants 19,375 - Series C Warrants as if converted at alternate cashless exercise prices * 8,874,955,625 - Unvested restricted stock units 59 59 Convertible Debt 529,536,021 71,349,657 Total 11,405,007,128 71,459,136 * Only convertible ratably upon exercise of Series B Warrants Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on its condensed consolidated financial statements. PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited)

GOING CONCERN

GOING CONCERN	9 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the nine months ended March 31, 2023, the Company had no revenues, had a net loss of $ 1,912,522 927,278 2,963,642 2,941,414 63,878,972 The unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful. In March 2020, the outbreak of COVID-19 (coronavirus) caused by a novel strain of the coronavirus was recognized as a pandemic by the World Health Organization, and the outbreak has become increasingly widespread in the United States, Europe and Australia, including in each of the areas in which the Company operates. The COVID-19 (coronavirus) outbreak has had a notable impact on general economic conditions, including but not limited to the temporary closures of many businesses, “shelter-in-place” and other governmental regulations, reduced business and consumer spending due to both job losses, reduced investing activity and M&A transactions, among many other effects attributable to the COVID-19 (coronavirus). While to date the Company has not been required to stop operating, management is evaluating its use of its office space, virtual meetings and the like.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following as of March 31, 2023 and June 30, 2022. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT March 31, 2023 June 30, 2022 (Unaudited) Office equipment at cost $ 25,559 $ 28,623 Less: Accumulated depreciation (24,925 ) (26,600 ) Total property, plant, and equipment $ 634 $ 2,023 Depreciation expense for the three months ended March 31, 2023 and 2022 were $ 450 490 1,345 1,503

DUE TO FORMER DIRECTOR _ RELATE

DUE TO FORMER DIRECTOR – RELATED PARTY	9 Months Ended
	Mar. 31, 2023
Due To Former Director Related Party
DUE TO FORMER DIRECTOR – RELATED PARTY	NOTE 4 – DUE TO FORMER DIRECTOR – RELATED PARTY Due to former director – related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company, such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amounts owed to the former director at March 31, 2023 and June 30, 2022 were $ 29,777 30,746

LOANS

LOANS	9 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
LOANS	NOTE 5 – LOANS Loan from Former Director – Related Party Loans from the Company’s former director at March 31, 2023 and June 30, 2022 were $ 49,558 51,171 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Loan Payable Crown Bridge Securities Purchase Agreement Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC (“Crown Bridge”), pursuant to which Crown Bridge purchased a convertible promissory note from the Company (the “Crown Bridge Note”), which had a remaining principal balance of $ 65,280 October 3, 2020 15 65,280 43,520 33,281 Loan in default The Crown Bridge Note is currently past due and in default, consisting of $ 65,280 30,866 15

CONVERTIBLE NOTES

CONVERTIBLE NOTES	9 Months Ended
	Mar. 31, 2023
Convertible Notes
CONVERTIBLE NOTES	NOTE 6 – CONVERTIBLE NOTES Convertible Notes Payable The Company’s convertible notes outstanding at March 31, 2023 and June 30, 2022 were as follows: SCHEDULE OF NOTES PAYABLE CONVERTIBLE DEBT March 31, 2023 June 30, 2022 (Unaudited) Convertible notes and debenture $ 473,361 $ 644,980 Unamortized discounts (103,932 ) (31,669 ) Premium, net 150,289 313,127 Convertible notes, net $ 519,718 $ 926,438 Coventry Enterprises, LLC Securities Purchase Agreement On November 3, 2022, the Company entered into a Securities Purchase Agreement with Coventry Enterprises, LLC (“Coventry”), pursuant to which the Company issued Coventry a promissory note from the Company in the aggregate principal amount of $ 125,000 25,000 100,000 The Coventry Note bears interest at a rate of 10 12,500 19,643 Additionally, in the event that the Company files with the SEC a qualified offering statement on Form 1-A and such note has been outstanding for four months since its issuance, Coventry has the right to convert all or portion of such note, including guaranteed interest, into shares of common stock at the offering price used in connection with such offering. At any time following an event of default under the Coventry Note, it becomes convertible, in whole or in part, into shares of Common Stock at the option of Coventry, at any time and from time to time thereafter (subject to the beneficial ownership limitations set forth therein). The conversion price of the Coventry Note is ninety percent (90%) per share of the lowest per-share VWAP during the twenty (20) trading-day period before the conversion (each, a “Calculated Conversion Price”). In the event that, within 30 calendar days either before or after any conversion, the conversion price of which is based upon a Calculated Conversion Price, the Company consummates (in whole or in part) any financing (whether such financing is equity, equity-equivalent, or debt or any combination thereof) or for any other reason issues any shares of common stock or any common stock equivalents at a price less than the most recent Calculated Conversion Price (the “Alternative Conversion Price”), regardless of when that note or instrument was originated, then, at the option of Coventry, (i) if the conversion has not yet occurred, then the Alternative Conversion Price will be substituted for the Calculated Conversion Price and (ii) if the conversion has occurred, then, within two trading days following Coventry’s written request, the Company is required to issue to Coventry that number of shares of Common Stock equivalent to the difference between the number of shares of Common Stock that had been issued using the Calculated Conversion Price and the number of shares of Common Stock that would have been issued using the Alternative Conversion Price. Accordingly, the Coventry note is treated as stock settled debt under ASC 480 and the Company recorded a total of $ 13,889 Upon the occurrence and during the continuation of certain events of default, interest on the Coventry Note accrues at a default interest rate equal to the lesser of (i) 18% per annum or (ii) the maximum rate permitted by law. Subject to the beneficial ownership limitation in the Coventry Note, if any event of default occurs, then the outstanding principal amount guaranteed interest plus accrued but unpaid default rate interest, liquidated damages and other amounts owing on the Coventry Note through the date of acceleration becomes immediately due and payable at Coventry’s option, in cash or in shares of common stock at the mandatory default amount, which is equal to 120% of all such amounts due on the Coventry Note. If the Company fails to deliver to Coventry such shares, the Company is required to pay in cash an amount equal to the amount that the value of such shares exceeds the principal amount and interest of the attempted conversion. As an additional inducement to Coventry entering into such agreement, the Company issued to Coventry 75,000,000 37,500 The Company failed to make the first installment payment due in March 2023 which is considered an event of default. Additional money owed to Coventry due to default is considered de minimis as of March 31, 2023. The total principal amount outstanding under the Coventry Note was $ 125,000 5,103 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Convertible Note Issued with Consulting Agreement August 10, 2017 Consulting Agreement On August 10, 2017, the Company entered into a consulting agreement, retroactive to May 16, 2017, with a certain consultant, pursuant to which the consultant agreed to provide certain consulting and business advisory services in exchange for a $ 310,000 August 10, 2019 10 750 65 ten August 10, 2019 155,000 155,000 18 578,212 140,000 10,764 161,000 19,418 9,000 500 5,248 8,500 22,168 On March 15, 2021, the Company entered into a Settlement and Mutual Release Agreement (the “Settlement Agreement”) with the consultant, whereby both parties agreed to settle all claims and liabilities under the August 10, 2017 convertible note for a total of $ 100,000 56,762 8,500 23,262 25,000 43,238 The total principal and accrued interest outstanding under the August 10, 2017 convertible note was $ 79,000 10,185 1,000 8,000 The total principal and accrued interest outstanding under the August 10, 2017 Convertible Note was $ 0 79,000 9,543 Crown Bridge Securities Purchase Agreements Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge, pursuant to which Crown Bridge purchased the Crown Bridge Note from the Company in the aggregate principal amount of $ 108,000 3,000 5,000 100,000 October 3, 2020 15 Additionally, Crown Bridge had the option to convert all or any amount of the Crown Bridge Note at any time after issuance until the later of such note’s maturity date or the date on which the default amount was paid if an event of default occurs, which would be between 110 150 The conversion price of the Crown Bridge Note was equal to 60% (representing a 40% discount) of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion under such note, including the day upon which such notice was received. 4.99 9.99 72,000 The Crown Bridge Note contained certain events of default, upon which principal and accrued interest would become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal accrued at a default interest rate of 15 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) The total principal amount outstanding under the Crown Bridge Note was $ 65,280 7,232 42,720 28,480 There were 15,000 st 9,600 6,400 16,000 The total principal amount outstanding under the Crown Bridge Note was $ 65,280 25,930 In August 2022, the SEC filed a complaint against Crown Bridge due to its violation of Section 15(a)(1) of the Exchange Act. Crown Bridge agreed to surrender all conversion rights in its currently held convertible notes, including the Crown Bridge Note. Consequently, as of March 31, 2023, the Company reclassified the remaining principal balance of $ 65,280 43,520 0 1800 Diagonal Lending (formerly known as Sixth Street Lending LLC) Securities Purchase Agreements October 21, 2021 Securities Purchase Agreement Effective October 21, 2021, the Company entered into a securities purchase agreement with Sixth Street Lending LLC (“Sixth Street”), pursuant to which Sixth Street purchased a convertible promissory note (the “October 21, 2021 Sixth Street Note”) from the Company in the aggregate principal amount of $ 63,750 3,750 October 21, 2022 8 November 26, 2021 Securities Purchase Agreement Effective November 26, 2021, the Company entered into a securities purchase agreement with Sixth Street, pursuant to which Sixth Street purchased a convertible promissory note (the “November 26, 2021 Sixth Street Note”) from the Company in the aggregate principal amount of $ 53,750 3,750 November 26, 2022 8 January 4, 2022 Securities Purchase Agreement Effective January 4, 2022, the Company entered into a securities purchase agreement with Sixth Street, pursuant to which Sixth Street purchased a convertible promissory note (the “January 4, 2022 Sixth Street Note”) from the Company in the aggregate principal amount of $ 63,750 3,750 January 4, 2023 8 March 7, 2022 Securities Purchase Agreement Effective March 7, 2022, the Company entered into a securities purchase agreement with Sixth Street, pursuant to which Sixth Street purchased a convertible promissory note (the “March 7, 2022 Sixth Street Note”) from the Company in the aggregate principal amount of $ 68,750 3,750 March 7, 2023 8 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) April 12, 2022 Securities Purchase Agreement Effective April 12, 2022, the Company entered into a securities purchase agreement with Sixth Street, pursuant to which Sixth Street purchased a convertible promissory note (the “April 12, 2022 Sixth Street Note”) from the Company in the aggregate principal amount of $ 68,750 3,750 April 12, 2023 8 May 12, 2022 Securities Purchase Agreement Effective May 12, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), pursuant to which 1800 Diagonal purchased a convertible promissory note (the “May 12, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 63,750 3,750 May 12, 2023 8 June 30, 2022 Securities Purchase Agreement On June 30, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal, which closed on July 11, 2022, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 11, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 105,000 3,750 June 30, 2023 8 The following terms apply to all of the above 1800 Diagonal notes: During the first 60 to 180 days following the date of the above listed notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 The conversion price for the above 1800 Diagonal notes is equal to 65 9.99 262,500 56,538 The above 1800 Diagonal notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal accrues at a default interest rate of 22 Such events of default include, among others, failure to timely issue shares upon receipt of a notice of conversion, breach of covenants, representations or warranties, insolvency, bankruptcy and liquidation (subject to cure periods), failure by the Company to pay the principal and interest due under such note, failure to reserve at least five times the number of shares issuable upon full conversion of such note, failure to maintain the listing of the common stock on at least one of the OTC markets or a national exchange, restatement of the Company’s financial statements at any time after 180 days after the issuance date of such note if such restatement would reasonably constitute a material adverse effect on 1800 Diagonal, the Company’s failure to comply with Exchange Act reporting requirements or the Company ceases to be subject to such reporting requirements. Failure to deliver shares of common stock upon conversion of the above 1800 Diagonal notes within three business days of a notice of conversion will result in the Company paying a penalty of $ 1,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Upon certain events of default, the above 1800 Diagonal notes will become immediately due and payable and the Company must pay 1800 Diagonal 150 The total principal amount outstanding under the above 1800 Diagonal notes was $ 265,000 6,081 117,500 4,700 63,269 The total principal amount outstanding and accrued interest under the above 1800 Diagonal notes was $ 0 370,000 14,800 199,230 ONE44 Capital Securities Purchase Agreements December 7, 2021 Securities Purchase Agreement Effective December 7, 2021, the Company entered into a securities purchase agreement with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “December 7, 2021 ONE44 Note”) from the Company in the aggregate principal amount of $ 170,000 25,500 December 7, 2022 10 March 29, 2022 Securities Purchase Agreement Effective March 29, 2022, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible promissory note (the “March 29, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 120,000 18,000 March 29, 2023 10 August 15, 2022 Securities Purchase Agreement On August 15, 2022, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 110,000 , such principal and the interest thereon convertible into shares of the common stock at the option of ONE44 any time after the six-month anniversary of the August 15, 2022 ONE44 Note. The transaction contemplated by such purchase agreement closed on August 16, 2022. The August 15, 2022 One44 Note contains an original issue discount amount of $ 10,000 . Pursuant to the terms of such purchase agreement, the Company paid $ 5,500 August 15, 2023 The August 15, 2022 ONE44 Note bears interest at a rate of 10 % per annum, which is payable in shares of common stock, but is not payable until the maturity date or upon acceleration or by prepayment of such note. February 14, 2023 Securities Purchase Agreement On February 14, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “February 14, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 111,111 , such principal and the interest thereon convertible into shares of the common stock at the option of ONE44 any time after the six-month anniversary of the February 14, 2023 ONE44 Note. The transaction contemplated by such purchase agreement closed on February 14, 2023. The February 14, 2023 One44 Note contains an original issue discount amount of $ 11,111 . Pursuant to the terms of such purchase agreement, the Company paid $ 5,500 February 14, 2024 10 The following terms apply to all of the above ONE44 notes: During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe ONE44 under the terms of the note, at a premium ranging from 120 135 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) The conversion price for the above ONE44 notes ranges from 60 % to 65 % (representing a 35% to 40% discount) of the market price of the common stock, which is based on the lowest closing bid prices of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion. Notwithstanding the foregoing, such notes are subject to 4.99% beneficial ownership limitations. All of the above ONE44 notes are treated as stock settled debt under ASC 480 and accordingly the Company recorded a total of $ 289,459 put premium of which $ 133,305 was recorded during the nine months ended March 31, 2023. The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 250 th 500 th 20 The total principal amount outstanding under the above ONE44 notes was $ 235,700 9,519 54,300 2,873 29,238 The total principal amount outstanding under the above ONE44 notes was $ 173,111 5,213 283,700 20,218 152,761 GS Capital Partners Securities Purchase Agreements August 12, 2022 Securities Purchase Agreement On August 12, 2022, the Company entered into a securities purchase agreement (the “GS Capital Purchase Agreement”) with GS Capital Partners, LLC (“GS Capital”), pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 93,000 , such principal and the interest thereon convertible into shares of common stock at the option of GS Capital. The transaction contemplated by the GS Capital Purchase Agreement closed on August 16, 2022. The GS Capital Note contains a $ 5,000 original issue discount. Pursuant to the terms of the GS Purchase Agreement, the Company paid $ 3,000 85,000 The maturity date of the GS Capital Note was April 12, 2023 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $0.0028 per share (the “Fixed Price”). However, in the event the common stock trades below $0.002 per share for more than five consecutive trading days, then the Fixed Price becomes $0.0013 per share. 65 4.99 Additionally, such conversion price will be adjusted if the Company issues securities with more favorable conversion terms. Currently, the effective conversion price of this note is 60 September 21, 2022 Securities Purchase Agreement On September 21, 2022, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 71,500 , such principal and the interest thereon convertible into shares of common stock at the option of GS Capital. The transaction contemplated by such purchase agreement closed on September 26, 2022. Such note contains a $ 4,000 original issue discount. Pursuant to the terms of such purchase agreement, the Company paid $ 2,500 65,000 ) from such note for general working capital purposes. The maturity date of such note is March 21, 2023 8 Such note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $0.002 (the “September Fixed Price”). However, in the event the common stock trades below $0.0014 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.0009 per share. 65 4.99 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Additionally, the conversion price will be adjusted in favor of the note holder if the Company issues securities with more favorable conversion terms. Currently, the effective conversion price of this note is 60 During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe GS Capital under the terms of the notes, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24 250 th 500 th 20 The total principal outstanding and accrued interest under the above GS Capital notes were $ 121,500 4,885 43,000 2,945 121,500 Red Road Holdings Securities Purchase Agreement On October 6, 2022, the Company entered into a securities purchase agreement (the “Red Road Purchase Agreement”) with Red Road Holdings Corporation, a Virginia corporation (“Red Road”), pursuant to which Red Road purchased a convertible promissory note (the “Red Road Note”) from the Company in the aggregate principal amount of $ 53,750 50,000 8 22 3,750 The conversion price for the Red Road Note is equal to the Variable Conversion Price (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Company relating to the Company’s securities or the securities of any subsidiary of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events), which is defined as 65% of the Market Price (representing a discount rate of 35%) which is defined as the average of the lowest three (3) Trading Prices (as defined in the Red Road Note) for the common stock during the ten (10) trading days prior to the conversion date. The Red Road Note is subject to 4.99 28,942 The Red Road Note may be prepaid until 180 days from its issuance date, subject to the following: if prepaid within 60 days of the issuance date, the prepayment premium is 110% of the face amount of such note plus any accrued interest, if prepaid after 60 days but less than 91 days from the issuance date, then the prepayment premium is 115% of the face amount plus any accrued interest of such note., if prepaid after 90 days but less than 121 days from the issuance date, then the prepayment premium is 120% of the face amount plus any accrued interest of such note, if prepaid after 120 days but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest of such note, and if prepaid after 150 days but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest of such note. In the event that the Company fails to deliver to Red Road shares of common stock upon conversion of the Red Road Note within three business days of a notice of conversion by Red Road, the Company incurs a penalty of $1,000 The total principal amount outstanding under the above Red Road Note was $ 53,750 2,073 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Amortization of debt discounts The Company recorded $ 210,278 66,000 232,674 380,961 Amortization of all debt discounts for the three months ended March 31, 2023 and 2022 was $ 54,111 13,647 138,014 24,942 The Company reclassified $ 351,992 227,150

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	9 Months Ended
	Mar. 31, 2023
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 7 – STOCKHOLDERS’ DEFICIT Increase in Authorized Shares of Common Stock and Reverse Stock Split On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its certificate of incorporation, as amended (the “Certificate of Incorporation”), which increased the Company’s authorized capital stock. Such certificate of amendment increased the number of authorized shares of common stock from 1,000,000,000 to 3,000,000,000 shares . The number of authorized shares of preferred stock remained at 1,500,005 shares , such that the total number of authorized shares of capital stock increased to 3,001,500,005 shares. Such certificate of amendment was filed and became effective on July 6, 2022. On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its Certificate of Incorporation, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of common stock from 3,000,000,000 to 10,000,000,000 shares . The number of authorized shares of preferred stock remained at 1,500,005 , such that the total number of shares of authorized capital stock increased to 10,001,500,005 shares. Such certificate of amendment was filed and became effective on November 4, 2022. Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005 0.01 Of the total preferred shares authorized, 500,000 On March 15, 2023, the Company filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Series A Preferred Stock to eliminate such Series A Preferred Stock. No none 500,000 Pursuant to a certificate of designation filed with the Secretary of State of the State of Delaware on June 16, 2015, five shares of preferred stock have been designated as Series B Preferred Stock, par value $0.01 per share, of the Company (“Series B Preferred Stock”). Each holder of shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of the Company. One No PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Common Stock: Shares issued for Common Stock Purchase Agreement Dutchess Capital Growth Fund LP On November 30, 2021, the Company entered into a Common Stock Purchase Agreement (the “Dutchess Purchase Agreement”) with Dutchess Capital Growth Fund LP, a Delaware limited partnership (“Dutchess”), providing for an equity financing facility (the “Dutchess Equity Line”). The Dutchess Purchase Agreement provides that, upon the terms and subject to the conditions in the Dutchess Purchase Agreement, Dutchess is committed to purchase up to Five Million Dollars ($ 5,000,000 36 Under the terms of the Dutchess Purchase Agreement, Dutchess will not be obligated to purchase shares of common stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 becoming effective, which registers Dutchess’ resale of any common stock purchased by Dutchess under the Dutchess Equity Line. From time to time over the 36-month term of the Dutchess Purchase Agreement, commencing on the trading day immediately following the date on which such registration statement becomes effective, the Company, in its sole discretion, may provide Dutchess with a draw down notice (each, a “Dutchess Draw Down Notice”), to purchase a specified number of shares of common stock (each, a “Dutchess Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Dutchess Draw Down Notice (each, a “Dutchess Draw Down Amount”) is to be determined by multiplying the Dutchess Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of common stock equals 92 The maximum number of shares of common stock requested to be purchased pursuant to any single Dutchess Draw Down Notice cannot exceed the lesser of (i) 300 250,000 On July 13, 2022, the Company issued 14,336,712 0.002 24,711 23,758 Coventry Enterprises, LLC On November 3, 2022, the Company entered into a Common Stock Purchase Agreement (the “Coventry Purchase Agreement”) with Coventry providing for an equity financing facility (the “Coventry Equity Line”). The Purchase Agreement provides that, upon the terms and subject to the conditions in the Purchase Agreement, Coventry is committed to purchase up to Five Million Dollars ($ 5,000,000 36 Under the terms of the Coventry Purchase Agreement, Coventry will not be obligated to purchase shares of common stock unless and until certain conditions are met, including but not limited to a registration statement on Form S-1 becoming effective which registers Coventry’s resale of any common stock purchased by Coventry under the Coventry Equity Line. From time to time over the 36-month term of the Coventry Purchase Agreement, commencing on the trading day immediately following the date on which such registration statement becomes effective, the Company, in its sole discretion, may provide Coventry with a draw down notice (each, a “Coventry Draw Down Notice”), to purchase a specified number of shares of common stock (each, a “Coventry Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Coventry Draw Down Notice (each, a “Coventry Draw Down Amount”) is to be determined by multiplying the Coventry Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of common stock equals 80% of the lowest volume weighted average price of the Common Stock during the 10 business days immediately preceding the Coventry Drawdown Notice date. The maximum number of shares of common stock requested to be purchased pursuant to any single Coventry Draw Down Notice cannot exceed the lesser of (i) 200 250,000 9.99 Shares issued for conversion of convertible debt As of June 30, 2022, there were 7,326,007 From July 1, 2022 through September 14, 2022, the Company issued an aggregate of 264,492,661 0.001 327,200 22,330 456,939 From October 17, 2022 through December 27, 2022, the Company issued an aggregate of 380,506,070 0.001 158,500 7,191 165,691 From January 5, 2023 through March 30, 2023, the Company issued an aggregate of 1,375,598,285 0.0002 290,000 17,985 435,198 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) The Company reclassified $ 351,992 During the nine months ended March 31, 2023, principal amount of convertible notes of $ 122,000 12,488 369,110, 234,622 223,288 11,334 The Company has 5,742,519,659 Shares issued for services and accrued expenses As of June 30, 2022, there was common stock issuable of 12,270,958 12,270,958 On October 25, 2022, the Company issued 6,111,112 0.0009 5,500 On November 16, 2022, the Company issued 73,301,020 0.00007 51,311 51,311 Shares issued upon exercise of warrants Between July 29, 2022 and December 6, 2022, the Company received gross proceeds of $ 200,000 5,000 5,000 Between February 7, 2023 and March 9, 2023, the Company received gross proceeds of $ 175,000 from the exercise of 4,375 Series B Warrants for 4,375 shares of common stock, which were issued in April 2023. During the nine months ended March 31, 2023, the Company issued 191,999,040 960 200 0.001 200 70 0 408,557 Shares issued in connection with a convertible note On November 3, 2022, the Company entered into a securities purchase agreement with Coventry, pursuant to which Coventry purchased a promissory note from the Company in the aggregate principal amount of $ 125,000 75,000,000 37,500 Restricted Stock Units Pursuant to employment agreements dated in May 2019, the Company granted an aggregate of 78 39 117 117 4,250 497,240 248,620 59 248,620 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Warrants: The following table summarizes common stock warrant activity for the nine months ended March 31, 2023: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2022 105,420 $ 200.27 Granted 3,305,000 0.01 Exercised (10,335 ) 54.86 Forfeited (1,000 ) 2,000.00 Expired - - Outstanding at March 31, 2023 3,399,085 * $ 5.51 Exercisable at March 31, 2023 3,379,711 $ 5.55 Outstanding and Exercisable: Weighted average remaining contractual term 2.38 Aggregate intrinsic value $ - * The 3,399,085 SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 9,986 9,986 Series B warrants 19,375 19,375 Series C warrants 63,749 44,375 Warrants with no class designation 3,305,975 3,305,975 Total 3,399,085 3,379,711 On August 16, 2022, the Company entered into an agreement with a certain consultant to provide services over a three-month period in exchange for 1,000,000 0.01 August 16, 2025 2,408 0.0026 0.01 zero 3.00 3.19 236 2,408 On August 16, 2022, the Company and a third-party investor relations consultant agreed to settle an outstanding payable of $ 23,050 2,305,000 0.01 5,551 0.0026 0.01 zero 3.00 3.19 236 17,499 On March 8, 2023, the Company agreed with the holder of Series B Warrants (the “Holder”) pursuant to a letter agreement to exercise up to $ 250,000 1. Effective upon the execution of such letter agreement, the Holder will exercise the existing 3,750 150,000 3,750 2. Within 5 business days’ written notice to the Holder from the Company of receipt of approval by the Financial Industry Regulatory Authority, Inc. (“FINRA”) of the Company’s next anticipated reverse stock split, an additional $ 100,000 2,500 As an inducement to exercise the Existing Warrants, the Company agreed to extend the termination date of the Existing Warrants and the Series A Warrants held by the Holder to March 27, 2025, and to extend the termination date of the Series C Warrants held by the Holder to the third anniversary of the last vesting date of such warrants, effective upon the exercise of the first $ 150,000 In accordance with ASC 815-40-35-17(c), the effect of a modification or an exchange of an equity classified freestanding written call option shall be measured as the difference between the fair value of the modified instrument and the fair value of that instrument immediately before it is modified. The Company recognized the effect of the modifications of the warrants above that is directly attributable to an actual equity offering as an equity issuance cost which amount is not material. The modified warrants are determined to be equity classified, accordingly, the incremental fair value and equity issuance cost were both recognized in additional paid in capital and therefore, there was no effect in equity and such value is de minimis. PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Options: A summary of the Company’s option activity during the nine months ended March 31, 2023 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Exercise Shares Price Per Share Outstanding at June 30, 2022 59 $ 4,533 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at March 31, 2023 59 $ 4,533 Exercisable at March 31, 2023 59 $ 4,533 Outstanding and Exercisable: Weighted average remaining contractual term 6.13 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ - In May 2019, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 234 shares of common stock for issuance under the 2019 Plan. Incentive awards authorized under the 2019 Plan include, but are not limited to, incentive stock options, non-qualified stock options, restricted stock awards and restricted stock units. During the nine months ended March 31, 2023 and 2022, the Company recognized stock-based compensation of $ 0 41,436 0 No

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be subject to litigation and claims arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceeding against the Company that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $ 10,000 30,000 Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “UK University”), whereby the Company and the UK University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property, while agreeing to pay royalties of 2 5 Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 59,508 40,000 5,775 31,754 36,117 28,493 24,043 2 30,000 35,145 5,000 5,000 5,858 10,000 11,715 10,000 11,715 25,837 30,268 2 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) On July 27, 2022, the Company entered into a two-year research agreement with the University to provide certain research and experiment services to the Company. In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 2 53,200 53,806 - 18,200 18,407 - 8,000 8,091 - 7,000 7,080 - 10,000 10,114 - 10,000 10,114 The commencement date for the experiments was on September 1, 2022, and the estimated length of time for completion is 24 months. As of March 31, 2023 and June 30, 2022, the Company has $ 40,465 14,364 no Consulting Agreement On July 1, 2022, the Company and a consultant agreed to extend the term of a consulting agreement from July 1, 2022 to June 30, 2023 to provide media-related services for a monthly fee of $ 50,000 9.9 9.9 73,301,020 83,277 9.9 100,000 183,277 Operating Leases On May 4, 2022, the Company entered in a three 3,000 2,176 66,201 66,201 8 ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET March 31, 2023 June 30, 2022 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (21,677 ) (3,678 ) Right-of-use asset, net $ 44,524 $ 62,523 Operating lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY March 31, 2023 June 30, 2022 Office lease $ 66,201 $ 66,201 Reduction of lease liability (20,077 ) (3,277 ) Less: office lease, current portion (21,185 ) (20,605 ) Long term portion of lease liability $ 24,939 $ 42,319 Remaining future minimum lease payments under the non-cancelable operating lease at March 31, 2023 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2023 (remaining) $ 6,027 Fiscal Year 2024 24,109 Fiscal Year 2025 20,091 Imputed interest (4,103 ) Total operating lease liability $ 46,124 The weighted average remaining lease term for the operating lease is 2.02 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited)

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of March 31, 2023 and June 30, 2022, the Company owed its former director a total of $ 29,777 30,746 As of March 31, 2023 and June 30, 2022, the Company owed its former director a total of $ 49,558 51,171 On May 4, 2022, the Company entered into a three 3,000 2,176 149,129 99,872 122,129 84,452 22,244 19,680 Employment and Services Agreements with Management The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz’s employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019 25,000 300,000 205,680 9.5 200 300,000 205,680 400,000 274,240 400,000 276,600 600,000 414,900 Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive, part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $ 120,000 80,904 Pursuant to a February 25, 2016 board resolution, James Nathanielsz is paid $ 4,481 3,205 7,689 5,577 Pursuant to the approval of the Company’s board of directors (the “Board”), on May 14, 2019, Mr. Nathanielsz was granted a $ 460,000 315,376 200,000 137,120 260,000 178,256 90,000 64,377 240,000 60 202,620 136,606 407,380 280,726 177,840 221,890 166,418 422,610 316,957 177,840 5,928,000 140,000 96,810 144,166 99,691 181,324 125,386 48,387 33,048 133,000 89,002 Amended and Restated Employment Agreement On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with Mr. Nathanielsz for a term of three years 400,000 309,313 39 4,675 110 4,250 39 39 10 39 39 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) On October 26, 2022, the Company entered into an Amended and Restated Employment Agreement (the “Amended Agreement”) with Mr. Nathanielsz, effective as of July 1, 2022, (the “2022 Effective Date”). The Amended Agreement provides Mr. Nathanielsz with a base salary of $ 600,000 414,900 100 200 Amended and Restated Employment Agreement On May 14, 2019, the Company entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years 54,000 41,580 20 4,250 100 20 20 10 20 20 On August 12, 2021, pursuant to a Cancellation Agreement, Mr. Kenyon agreed to cancel accrued salaries of $ 102,600 3,420,000 82,500 56,050 54,000 37,341 Collaboration Agreement On October 1, 2020, the Company entered into a two-year collaboration agreement with the University of Jaén to provide certain research services to the Company. One of the Company’s Scientific Advisory Board is the lead joint researcher of University of Jaén. Additionally, on July 27, 2022, the Company entered into a two-year research agreement with the University of Jaén to provide certain research and experiment services to the Company (see Note 8). Further, the Company agreed to pay royalties of 1% of net revenues each to two members of the Scientific Advisory Board. Intercompany Loans All intercompany loans were made by the parent to the Company’s subsidiary, Propanc PTY LTD, none of which has been repaid as of March 31, 2023. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment on the condensed consolidated balance sheet as accumulated other comprehensive income.

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	9 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND RISKS	NOTE 10 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through March 31, 2023. The Company primarily relied on funding from five convertible debt lenders and received net proceeds after deductions of $ 79,111 for original issue discounts and debt issue costs during the nine months ended March 31, 2023 from each of the five lenders of $ 101,250 189,000 150,000 50,000 100,000, 17 32 25 8 18 The Company primarily relied on funding from three convertible debt lenders and received proceeds after deductions of $ 66,000 641,500 160,000 235,000 246,500 23 33 35 Receivable Concentration As of March 31, 2023 and June 30, 2022, the Company’s receivables were 100 Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Republic of Korea, India and Brazil. In Canada and Mexico, the patent applications have been accepted as of this March 31 quarter. PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) In 2016 and early 2017, the Company filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third PCT application entered the national phase in October 2018. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 59 granted, allowed, or accepted patents and 17 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of March 31, 2023 and June 30, 2022, the Company’s operations are based in Camberwell, Australia; however, the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales, for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of March 31, 2023 and June 30, 2022, there has been no activity within this entity.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	9 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 11 – DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity 121,500 79,000 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at March 31, 2023, the last trading day of the period ended March 31, 2023, was $ 0.0005 Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the nine March 31, 2023 Volatility 228.29 256.02 267.38 % Expected Remaining Term (in years) 0.22 0.28 0.01 0.03 Risk Free Interest Rate 3.13 4.42 4.74 % Expected dividend yield None None PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and June 30, 2022: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 132,501 $ — $ — $ 132,501 Total $ 132,501 $ — $ — $ 132,501 Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 151,262 $ — $ — $ 151,262 Total $ 151,262 $ — $ — $ 151,262 The following is a roll forward for the nine months ended March 31, 2023 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2022 $ 151,262 Initial fair value of embedded conversion option derivative liability recorded as debt discount 93,668 Reduction of derivative liability upon debt conversion (223,288 ) Change in fair value included in statements of operations 110,859 Balance at March 31, 2023 $ 132,501

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS Shares issued for conversion of convertible debt Between April 2023 and May 2023, the Company issued an aggregate of 667,102,561 0.0002 112,750 6,433 48,865 Reverse Stock Split On May 1, 2023, the Company effected a one-for-one thousand (1:1,000) reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Stock Split”). No fractional shares of Common Stock will be issued in connection with the Reverse Stock Split, all of which were rounded up to the nearest whole number. The following is the unaudited pro-forma effect of the 1:1000 Reverse Stock Split on the basic and diluted net loss per share: SCHEDULE OF REVERSE STOCK SPLIT Historical per share data – (Pre- Split basis) Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended (Unaudited) (Unaudited) (Unaudited) (Unaudited) Net loss available to Common Stockholders $ 809,809 $ 700,076 $ 2,321,079 $ 2,198,953 Basic and diluted weighted average shares outstanding 1,924,073,522 66,353,881 1,115,848,071 47,561,123 Basic and diluted net loss per share $ 0.00 $ 0.01 $ 0.00 $ 0.05 Historical per share data – (Post- Split basis) (Unaudited) Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended (Unaudited) (Unaudited) (Unaudited) (Unaudited) Net loss available to Common Stockholders $ 809,809 $ 700,076 $ 2,321,079 $ 2,198,953 Basic and diluted weighted average shares outstanding 1,924,074 66,354 1,115,848 47,561 Basic and diluted net loss per share $ 0.42 $ 10.55 $ 2.08 $ 46.23 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) The following is the unaudited pro-forma effect of the 1:1000 Reverse Stock Split on the condensed consolidated balance sheets: SCHEDULE OF PRO FORMA EFFECT OF REVERSE STOCK SPLIT March 31, 2023 1:1000 adjustment Pro-Forma Effect (Unaudited) Total Assets $ 143,742 $ - $ 143,742 Total Liabilities 3,085,156 - 3,085,156 Stockholders’ Deficit: Common Stock 2,621,298 (2,618,677 ) 2,621 Common Stock Issuable 4 (4 ) - Additional Paid In Capital 57,068,986 2,618,681 59,687,667 Subscription Receivable - - - Accumulated Other Comprehensive Income 1,293,747 - 1,293,747 Accumulated Deficit (63,878,972 ) - (63,878,972 ) Treasury Stock (46,477 ) - (46,477 ) Total Stockholders’ deficit (2,941,414 ) - (2,941,414 ) Total Liabilities and Basic and Stockholders’ deficit $ 143,742 $ - $ 143,742 June 30, 2022 1:1000 adjustment Pro-Forma Effect June 30, 2022 (Unaudited) Total Assets $ 81,651 $ - $ 81,651 Total Liabilities 3,105,300 - 3,105,300 Stockholders’ Deficit: Series A Preferred Stock 5,000 - 5,000 Common Stock 220,351 (220,131 ) 220 Common Stock Issuable 19,597 (19,577 ) 20 Additional Paid In Capital 57,124,982 239,708 57,364,690 Subscription Receivable (23,758 ) - (23,758 ) Accumulated Other Comprehensive Income 1,234,549 - 1,234,549 Accumulated Deficit (61,557,893 ) - (61,557,893 ) Treasury Stock (46,477 ) - (46,477 ) Total Stockholders’ deficit (3,023,649 ) - (3,023,649 ) Total Liabilities and Basic and Stockholders’ deficit $ 81,651 $ - $ 81,651

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of March 31, 2023, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 59 granted, allowed, or accepted patents and 17 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.
Basis of Presentation	Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three and nine months ended March 31, 2023 and 2022 and cash flows for the three and nine months ended March 31, 2023 and 2022, and our consolidated financial position at March 31, 2023 have been made. The Company’s results of operations for the nine months ended March 31, 2023 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2023. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2022. The June 30, 2022 balance sheet is derived from those statements.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All intercompany balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through March 31, 2023. PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited)
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of March 31, 2023 and 2022, the Company recognized a cumulative exchange gain (loss) of approximately $ 556,000 15,600 As of March 31, 2023 and June 30, 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES March 31, 2023 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6697 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6794 0.7253 The change in Accumulated Other Comprehensive Income by component during the nine months ended March 31, 2023 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2022 $ 1,234,549 Unrealized foreign currency translation gain 59,198 Ending balance, March 31, 2023 $ 1,293,747
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited) The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 – Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
Patents	Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as it is in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through March 31, 2023 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Employee Benefit Liability	Employee Benefit Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months.
Australian Goods and Services Tax (“GST”)	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of March 31, 2023, and June 30, 2022, the Company was owed $ 3,334 2,342 PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited)
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes With Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $0.001 per share (“common stock”) at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 66,020 50,395 242,223 147,702 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. During each of the nine months ended March 31, 2023 and 2022, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 131,037 55,250
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. PROPANC BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 (Unaudited)
Legal Expenses	Legal Expenses All legal costs for litigation are charged to expense as incurred.
Leases	Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operations and relate to the presentation of accrued interest separately on the consolidated balance sheet, of which $ 57,822
Basic and Diluted Net Loss Per Share of Common Stock	Basic and Diluted Net Loss Per Share of Common Stock Basic net loss per share of common stock is computed by dividing the net loss by the weighted average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants, restricted stock units and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per-share amounts for all periods presented are identical. Each holder of the notes and warrants has agreed to a 4.99 The Company’s CEO holds Series B Preferred Stock that, when combined, confers upon him a majority vote , including SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS March 31, 2023 March 31, 2022 (Unaudited) (Unaudited) Stock Options 59 59 Warrants with no designations 3,305,975 109,361 Series A Warrants as if converted at alternate cashless exercise prices 1,997,190,014 - Series B Warrants 19,375 - Series C Warrants as if converted at alternate cashless exercise prices * 8,874,955,625 - Unvested restricted stock units 59 59 Convertible Debt 529,536,021 71,349,657 Total 11,405,007,128 71,459,136 * Only convertible ratably upon exercise of Series B Warrants
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on its condensed consolidated financial statements.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF TRANSLATION EXCHANGE RATES	As of March 31, 2023 and June 30, 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES March 31, 2023 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6697 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6794 0.7253
SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS	The change in Accumulated Other Comprehensive Income by component during the nine months ended March 31, 2023 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2022 $ 1,234,549 Unrealized foreign currency translation gain 59,198 Ending balance, March 31, 2023 $ 1,293,747
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE	The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS March 31, 2023 March 31, 2022 (Unaudited) (Unaudited) Stock Options 59 59 Warrants with no designations 3,305,975 109,361 Series A Warrants as if converted at alternate cashless exercise prices 1,997,190,014 - Series B Warrants 19,375 - Series C Warrants as if converted at alternate cashless exercise prices * 8,874,955,625 - Unvested restricted stock units 59 59 Convertible Debt 529,536,021 71,349,657 Total 11,405,007,128 71,459,136 * Only convertible ratably upon exercise of Series B Warrants

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consist of the following as of March 31, 2023 and June 30, 2022. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT March 31, 2023 June 30, 2022 (Unaudited) Office equipment at cost $ 25,559 $ 28,623 Less: Accumulated depreciation (24,925 ) (26,600 ) Total property, plant, and equipment $ 634 $ 2,023

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	9 Months Ended
	Mar. 31, 2023
Convertible Notes
SCHEDULE OF NOTES PAYABLE CONVERTIBLE DEBT	The Company’s convertible notes outstanding at March 31, 2023 and June 30, 2022 were as follows: SCHEDULE OF NOTES PAYABLE CONVERTIBLE DEBT March 31, 2023 June 30, 2022 (Unaudited) Convertible notes and debenture $ 473,361 $ 644,980 Unamortized discounts (103,932 ) (31,669 ) Premium, net 150,289 313,127 Convertible notes, net $ 519,718 $ 926,438

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	9 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes common stock warrant activity for the nine months ended March 31, 2023: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2022 105,420 $ 200.27 Granted 3,305,000 0.01 Exercised (10,335 ) 54.86 Forfeited (1,000 ) 2,000.00 Expired - - Outstanding at March 31, 2023 3,399,085 * $ 5.51 Exercisable at March 31, 2023 3,379,711 $ 5.55 Outstanding and Exercisable: Weighted average remaining contractual term 2.38 Aggregate intrinsic value $ - * The 3,399,085
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE	SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 9,986 9,986 Series B warrants 19,375 19,375 Series C warrants 63,749 44,375 Warrants with no class designation 3,305,975 3,305,975 Total 3,399,085 3,379,711
SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY	A summary of the Company’s option activity during the nine months ended March 31, 2023 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Exercise Shares Price Per Share Outstanding at June 30, 2022 59 $ 4,533 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at March 31, 2023 59 $ 4,533 Exercisable at March 31, 2023 59 $ 4,533 Outstanding and Exercisable: Weighted average remaining contractual term 6.13 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ -

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF RIGHT OF USE ASSET	ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET March 31, 2023 June 30, 2022 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (21,677 ) (3,678 ) Right-of-use asset, net $ 44,524 $ 62,523
SCHEDULE OF OPERATING LEASE LIABILITY	Operating lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY March 31, 2023 June 30, 2022 Office lease $ 66,201 $ 66,201 Reduction of lease liability (20,077 ) (3,277 ) Less: office lease, current portion (21,185 ) (20,605 ) Long term portion of lease liability $ 24,939 $ 42,319
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS	Remaining future minimum lease payments under the non-cancelable operating lease at March 31, 2023 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2023 (remaining) $ 6,027 Fiscal Year 2024 24,109 Fiscal Year 2025 20,091 Imputed interest (4,103 ) Total operating lease liability $ 46,124

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES	SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the nine March 31, 2023 Volatility 228.29 256.02 267.38 % Expected Remaining Term (in years) 0.22 0.28 0.01 0.03 Risk Free Interest Rate 3.13 4.42 4.74 % Expected dividend yield None None
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 132,501 $ — $ — $ 132,501 Total $ 132,501 $ — $ — $ 132,501 Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 151,262 $ — $ — $ 151,262 Total $ 151,262 $ — $ — $ 151,262
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE	The following is a roll forward for the nine months ended March 31, 2023 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2022 $ 151,262 Initial fair value of embedded conversion option derivative liability recorded as debt discount 93,668 Reduction of derivative liability upon debt conversion (223,288 ) Change in fair value included in statements of operations 110,859 Balance at March 31, 2023 $ 132,501

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)	9 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SCHEDULE OF REVERSE STOCK SPLIT	SCHEDULE OF REVERSE STOCK SPLIT Historical per share data – (Pre- Split basis) Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended (Unaudited) (Unaudited) (Unaudited) (Unaudited) Net loss available to Common Stockholders $ 809,809 $ 700,076 $ 2,321,079 $ 2,198,953 Basic and diluted weighted average shares outstanding 1,924,073,522 66,353,881 1,115,848,071 47,561,123 Basic and diluted net loss per share $ 0.00 $ 0.01 $ 0.00 $ 0.05 Historical per share data – (Post- Split basis) (Unaudited) Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended (Unaudited) (Unaudited) (Unaudited) (Unaudited) Net loss available to Common Stockholders $ 809,809 $ 700,076 $ 2,321,079 $ 2,198,953 Basic and diluted weighted average shares outstanding 1,924,074 66,354 1,115,848 47,561 Basic and diluted net loss per share $ 0.42 $ 10.55 $ 2.08 $ 46.23
SCHEDULE OF PRO FORMA EFFECT OF REVERSE STOCK SPLIT	SCHEDULE OF PRO FORMA EFFECT OF REVERSE STOCK SPLIT March 31, 2023 1:1000 adjustment Pro-Forma Effect (Unaudited) Total Assets $ 143,742 $ - $ 143,742 Total Liabilities 3,085,156 - 3,085,156 Stockholders’ Deficit: Common Stock 2,621,298 (2,618,677 ) 2,621 Common Stock Issuable 4 (4 ) - Additional Paid In Capital 57,068,986 2,618,681 59,687,667 Subscription Receivable - - - Accumulated Other Comprehensive Income 1,293,747 - 1,293,747 Accumulated Deficit (63,878,972 ) - (63,878,972 ) Treasury Stock (46,477 ) - (46,477 ) Total Stockholders’ deficit (2,941,414 ) - (2,941,414 ) Total Liabilities and Basic and Stockholders’ deficit $ 143,742 $ - $ 143,742 June 30, 2022 1:1000 adjustment Pro-Forma Effect June 30, 2022 (Unaudited) Total Assets $ 81,651 $ - $ 81,651 Total Liabilities 3,105,300 - 3,105,300 Stockholders’ Deficit: Series A Preferred Stock 5,000 - 5,000 Common Stock 220,351 (220,131 ) 220 Common Stock Issuable 19,597 (19,577 ) 20 Additional Paid In Capital 57,124,982 239,708 57,364,690 Subscription Receivable (23,758 ) - (23,758 ) Accumulated Other Comprehensive Income 1,234,549 - 1,234,549 Accumulated Deficit (61,557,893 ) - (61,557,893 ) Treasury Stock (46,477 ) - (46,477 ) Total Stockholders’ deficit (3,023,649 ) - (3,023,649 ) Total Liabilities and Basic and Stockholders’ deficit $ 81,651 $ - $ 81,651

SCHEDULE OF TRANSLATION EXCHANG

SCHEDULE OF TRANSLATION EXCHANGE RATES (Details)	Mar. 31, 2023	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6697	0.6915
Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6794	0.7253

SCHEDULE OF ACCUMULATED OTHER C

SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS (Details)	9 Months Ended
	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 1,234,549
Foreign currency translation loss	59,198
Ending balance	$ 1,293,747

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE (Details)	Mar. 31, 2023
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	7 years

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS (Details) - shares		9 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		11,405,007,128	71,459,136
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		59	59
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		3,305,975	109,361
Series A Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		1,997,190,014
Series B Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		19,375
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]	8,874,955,625
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		59	59
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		529,536,021	71,349,657
[1]Only convertible ratably upon exercise of Series B Warrants

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Short-Term Debt [Line Items]
Cash and cash equivalents	$ 0		$ 0		$ 0
Value added tax receivable	3,334		3,334		2,342
Total research and development expense	66,020	$ 50,395	242,223	$ 147,702
Tax credit			131,037	55,250
Interest Payable	$ 56,661		$ 56,661		$ 57,822
Beneficial ownership conversion description			Each holder of the notes and warrants has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ abilities to increase such limitation to 9.99% upon 60 days’ notice to the Company), and certain notes may not be converted during the certain specified time period from the date of issuance.
beneficial ownership percentage			4.99%
Intercompany Loans [Member]
Short-Term Debt [Line Items]
Subsidiary exchange repayments			$ 556,000	$ 15,600

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 1,912,522
Operating activities	927,278	$ 1,025,306
Working capital deficit	2,963,642
Stockholders equity	2,941,414	$ 2,947,420	$ 2,915,417	$ 2,767,535	$ 3,023,649	$ 2,930,193	$ 2,306,630	$ 3,067,573
Retained earnings accumulated deficit	$ 63,878,972				$ 61,557,893

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Office equipment at cost	$ 25,559	$ 28,623
Less: Accumulated depreciation	(24,925)	(26,600)
Total property, plant, and equipment	$ 634	$ 2,023

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 450	$ 490	$ 1,345	$ 1,503

DUE TO FORMER DIRECTOR _ RELA_2

DUE TO FORMER DIRECTOR – RELATED PARTY (Details Narrative) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Related Party Transaction [Line Items]
Due to related parties current	$ 29,777	$ 30,746
Related Party [Member]
Related Party Transaction [Line Items]
Due to related parties current	$ 29,777	$ 30,746

LOANS (Details Narrative)

LOANS (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Oct. 03, 2019	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Nov. 30, 2020	Jun. 30, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Gain on extinguishment of debt		$ (10,724)		$ 32,186
Interest payable current and non current		$ 12,488		$ 12,488				$ 5,248
Crown Bridge Partners, LLC [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt instrument interest rate stated percentage		15%		15%
Debt instrument face amount		$ 65,280		$ 65,280
Interest payable current and non current		30,866		30,866
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Convertible debt	$ 65,280
Maturity date	Oct. 03, 2020
Debt instrument interest rate stated percentage	15%
Debt instrument face amount	$ 108,000	65,280		65,280		$ 65,280	$ 9,600	65,280
Gain on extinguishment of debt	$ 43,520			43,520
Interest payable current and non current		33,281		33,281		25,930		$ 7,232
Directors and Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Loans payable		$ 49,558		$ 49,558		$ 51,171

SCHEDULE OF NOTES PAYABLE CONVE

SCHEDULE OF NOTES PAYABLE CONVERTIBLE DEBT (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Convertible Notes
Convertible notes and debenture	$ 473,361	$ 644,980
Unamortized discounts	(103,932)	(31,669)
Premium, net	150,289	313,127
Convertible notes, net	$ 519,718	$ 926,438

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative)																									3 Months Ended					9 Months Ended		12 Months Ended					21 Months Ended
	Feb. 15, 2023	Feb. 14, 2023 USD ($)	Feb. 14, 2023 USD ($)	Nov. 03, 2022 USD ($) shares	Oct. 06, 2022 USD ($)	Sep. 21, 2022 USD ($)	Sep. 21, 2022 USD ($)	Sep. 21, 2022 USD ($)	Aug. 15, 2022 USD ($)	Aug. 12, 2022 USD ($)	Aug. 12, 2022 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 USD ($) shares	May 12, 2022 USD ($)	Apr. 12, 2022 USD ($)	Mar. 29, 2022 USD ($)	Mar. 07, 2022 USD ($)	Jan. 04, 2022 USD ($)	Dec. 07, 2021 USD ($)	Nov. 26, 2021 USD ($)	Oct. 21, 2021 USD ($)	Sep. 16, 2020 shares	Oct. 03, 2019 USD ($)	Aug. 10, 2017 USD ($) Integer $ / shares	Mar. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2023 USD ($) shares	Mar. 15, 2021 USD ($)	Nov. 30, 2020 USD ($)	Jun. 30, 2017 USD ($)
Debt conversion converted instrument																																		$ 500
Original issue discount												$ 31,669	$ 31,669												$ 103,932					$ 103,932		$ 31,669					$ 103,932
Proceeds from convertible debt																														590,250	$ 641,500
Debt instrument unamortized premium												$ 313,127	$ 313,127												$ 150,289					$ 150,289		$ 313,127					$ 150,289
Number of shares issued | shares												1	1												1					1		1					1
Amortization of debt discount																									$ 54,111			$ 13,647		$ 138,014	24,942
Accrued interest																									12,488					$ 12,488				5,248			$ 12,488
Lowest trading price percentage																														4.99%
Embedded derivative fair value of embedded derivative liability												$ 151,262	$ 151,262												132,501					$ 132,501		$ 151,262					132,501
Liabilities												3,105,300	3,105,300												3,085,156					3,085,156		3,105,300					3,085,156
Gain on extinguishment of debt																									(10,724)					32,186
Debt instrument amount												644,980	644,980												473,361					473,361		644,980					473,361
Penalty amount																														30,000
Original issue discounts amount																														79,111							66,000
Reduction of put premium related to conversions of convertible notes																									133,000	$ 85,346	$ 133,646	100,840	$ 16,667	351,992	227,150
Settlement and Mutual Release Agreement [Member]
Convertible notes payable																									122,000					122,000							$ 122,000
Gain on extinguishment of debt																														$ 11,334
Common Stock [Member]
Reduction of put premium related to conversions of convertible notes
Coventry Enterprises LLC Securities Purchase Agreement [Member]
Monthly payment amount				$ 19,643
Crown Bridge Partners, LLC [Member]
Debt instrument, interest rate, stated percentage																									15%					15%							15%
principal amount																									$ 65,280					$ 65,280							$ 65,280
Accrued interest																									30,866					30,866							30,866
1800 Diagonal Lending [Member]
Accrued interest												4,700	4,700												14,800					14,800		4,700					14,800
ONE44 Capital LLC [Member]
Debt instrument unamortized premium																									289,459					289,459							289,459
Accrued interest												2,873	2,873												20,218					20,218		2,873					20,218
GS Capital Partners, LLC [Member]
Accrued interest																									2,945					2,945							2,945
Securities Purchase Agreement [Member]
Original issue discount																									232,674			$ 380,961		232,674	380,961						232,674
Amortization of debt discount																														210,278	$ 66,000
Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Debt conversion converted instrument				125,000
Original issue discount				25,000
Proceeds from convertible debt				$ 100,000
Debt instrument, interest rate, stated percentage				10%
Debt instrument guaranteed interest				$ 12,500
Number of shares issued | shares				75,000,000
Amortization of debt discount				$ 37,500
principal amount				$ 125,000																					125,000					125,000							125,000
Accrued interest																									5,103					5,103							5,103
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Debt conversion converted instrument																																		42,720
Original issue discount																							$ 5,000
Debt instrument, interest rate, stated percentage																							15%
Debt instrument unamortized premium																							$ 72,000		13,889					13,889				28,480			13,889		$ 6,400
principal amount												65,280	65,280										$ 108,000		65,280					65,280		65,280		65,280			65,280		9,600
Accrued interest												$ 25,930	$ 25,930												33,281					33,281		$ 25,930		7,232			33,281
Debt instrument maturity date																							Oct. 03, 2020
Debt instrument debt default interest rate																							15%
Gain on extinguishment of debt																							$ 43,520							43,520
Debt instrument periodic payment principal																							$ 3,000
Debt instrument description																							The conversion price of the Crown Bridge Note was equal to 60% (representing a 40% discount) of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion under such note, including the day upon which such notice was received.
Unissued shares conversion | shares																						15,000
Equity conversion																																							$ 16,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | Minimum [Member]
Debt instrument debt default interest rate																							110%
Percentage of outstanding shares of common stock																							4.99%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | Maximum [Member]
Debt instrument debt default interest rate																							150%
Percentage of outstanding shares of common stock																							9.99%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member]
Proceeds from convertible debt																							$ 100,000
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member]
Debt conversion converted instrument																														370,000
Debt instrument, interest rate, stated percentage												8%	8%	8%	8%		8%	8%		8%	8%											8%
Debt instrument unamortized premium												$ 262,500	$ 262,500												199,230					199,230		$ 262,500					199,230
principal amount												$ 105,000	$ 105,000	$ 63,750	$ 68,750		$ 68,750	$ 63,750		$ 53,750	$ 63,750				0					$ 0		105,000					0
Debt instrument maturity date													Jun. 30, 2023	May 12, 2023	Apr. 12, 2023		Mar. 07, 2023	Jan. 04, 2023		Nov. 26, 2022	Oct. 21, 2022
Debt instrument debt default interest rate												65%
Debt instrument description													The conversion price for the above 1800 Diagonal notes is equal to 65% (representing a 35% discount) of the market price of the common stock, which is based on the average of the lowest three trading prices of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion of such note.
Percentage of outstanding shares of common stock																														150%
Debt issue costs													$ 3,750	$ 3,750	$ 3,750		$ 3,750	$ 3,750		$ 3,750	$ 3,750
Debt instrument amount																									56,538					$ 56,538							56,538
Debt default amount percentage													22%
Penalty amount																														1,000
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | Minimum [Member]
Debt instrument debt default interest rate													110%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | Maximum [Member]
Debt instrument debt default interest rate													129%
Percentage of outstanding shares of common stock													9.99%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member]
Debt conversion converted instrument																														283,700		54,300
Debt instrument, interest rate, stated percentage		10%	10%						10%							10%			10%
Debt instrument unamortized premium												$ 29,238	$ 29,238												152,761					152,761		29,238					152,761
principal amount		$ 111,111	$ 111,111						$ 110,000			235,700	235,700			$ 120,000			$ 170,000						173,111					173,111		235,700					173,111
Accrued interest												9,519	9,519												5,213					5,213		9,519					5,213
Debt instrument maturity date			Feb. 14, 2024						Aug. 15, 2023							Mar. 29, 2023			Dec. 07, 2022
Debt instrument description		The conversion price for the above ONE44 notes ranges from
Debt instrument amount																									133,305					133,305							133,305
Debt default amount percentage	24%
Original issue discounts amount																$ 18,000			$ 25,500
Debt Conversion, Original Debt, Amount			$ 11,111						$ 10,000
Legal fees and due diligence expenses			$ 5,500						$ 5,500
Debt instrument debt default interest rate						60%					60%
Debt principal increase percentage			20%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Minimum [Member]
Debt instrument debt default interest rate			120%
Penalty amount			$ 250
Debt instrument debt default interest rate			60%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Maximum [Member]
Debt instrument debt default interest rate			135%
Penalty amount			$ 500
Debt instrument debt default interest rate		65%
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Original issue discount						$ 4,000	$ 4,000	$ 4,000		$ 5,000	$ 5,000
Debt instrument, interest rate, stated percentage						8%	8%	8%		8%	8%
principal amount						$ 71,500	$ 71,500	$ 71,500		$ 93,000	$ 93,000														121,500					121,500							121,500
Accrued interest																									4,885					4,885							4,885
Debt instrument maturity date						Mar. 21, 2023					Apr. 12, 2023
Lowest trading price percentage							65%			65%
Debt instrument debt default interest rate						24%
Percentage of outstanding shares of common stock						4.99%					4.99%
Legal fees and due diligence expenses								2,500			$ 3,000
Debt principal increase percentage						20%
Proceeds from Issuance of Debt								$ 65,000			$ 85,000
Conversion price, description						Such note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $0.002 (the “September Fixed Price”). However, in the event the common stock trades below $0.0014 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.0009 per share.					The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $0.0028 per share (the “Fixed Price”). However, in the event the common stock trades below $0.002 per share for more than five consecutive trading days, then the Fixed Price becomes $0.0013 per share.
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]
Debt instrument debt default interest rate						110%
Penalty amount						$ 250
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]
Debt instrument debt default interest rate						125%
Penalty amount						$ 500
Securities Purchase Agreement [Member] | Red Road Holdings Securities Purchase Agreement [Member]
Proceeds from convertible debt					$ 50,000
Debt instrument, interest rate, stated percentage					8%
Debt instrument unamortized premium					$ 28,942
principal amount					$ 53,750																				53,750					53,750							53,750
Accrued interest																									2,073					2,073							2,073
Debt instrument debt default interest rate					22%
Debt instrument description					65% of the Market Price (representing a discount rate of 35%) which is defined as the average of the lowest three (3) Trading Prices (as defined in the Red Road Note) for the common stock during the ten (10) trading days prior to the conversion date. The Red Road Note is subject to 4.99% beneficial ownership limitations and is treated as stock settled debt under ASC 480, and accordingly the Company recorded a total of $28,942 put premium
Penalty amount					$ 1,000
Legal fees and due diligence expenses					$ 3,750
Percentage of outstanding shares of common stock					4.99%
Note prepayment pemium description					The Red Road Note may be prepaid until 180 days from its issuance date, subject to the following: if prepaid within 60 days of the issuance date, the prepayment premium is 110% of the face amount of such note plus any accrued interest, if prepaid after 60 days but less than 91 days from the issuance date, then the prepayment premium is 115% of the face amount plus any accrued interest of such note., if prepaid after 90 days but less than 121 days from the issuance date, then the prepayment premium is 120% of the face amount plus any accrued interest of such note, if prepaid after 120 days but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest of such note, and if prepaid after 150 days but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest of such note.
August 10, 2017 Consulting Agreement [Member]
Debt conversion converted instrument																								$ 310,000						79,000		1,000		8,500
Debt instrument, interest rate, stated percentage																								10%
principal amount																																			$ 9,000
Accrued interest												8,000	8,000												9,543					9,543		8,000		$ 22,168			9,543
Debt instrument maturity date																								Aug. 10, 2019
Lowest trading price percentage																								65%
Debt instrument convertible | Integer																								10
Accrued liabilities current and non current																																				$ 155,000				$ 155,000
Debt instrument debt default interest rate																								18%
Embedded derivative fair value of embedded derivative liability																								$ 578,212
August 10, 2017 Consulting Agreement [Member] | Settlement and Mutual Release Agreement [Member]
Debt conversion converted instrument																								$ 79,000
principal amount																																						$ 8,500
Accrued interest												10,185	10,185												0					0		10,185					0	23,262
Accrued liabilities current and non current																																						25,000
Convertible notes payable																																						100,000
Liabilities																																						$ 56,762
Gain on extinguishment of debt																																	$ 43,238
August 10, 2017 Consulting Agreement [Member] | Consultant [Member]
Debt conversion converted instrument																																			161,000	140,000
Accrued interest																																			$ 19,418	$ 10,764
August 10, 2017 Consulting Agreement [Member] | Common Stock [Member]
Debt convertible conversion price | $ / shares																								$ 750
August 10, 2017 Consulting Agreement [Member] | GS Capital Partners, LLC [Member]
Debt conversion converted instrument																														43,000
Crown Bridge Financing Agreement [Member] | Crown Bridge Partners, LLC [Member]
principal amount																									$ 0					$ 0							$ 0
6th Street Financing Agreement [Member] | 1800 Diagonal Lending [Member]
Debt conversion converted instrument																																117,500
Debt instrument unamortized premium												63,269	63,269																			63,269
principal amount												265,000	265,000																			265,000
Accrued interest												$ 6,081	$ 6,081																			$ 6,081

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details)	9 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance | shares	105,420
Weighted Average Price Per Share, Outstanding, Beginning balance | $ / shares	$ 200.27
Number of Shares, Issued | shares	3,305,000
Weighted Average Price Per Share, Issued | $ / shares	$ 0.01
Number of Shares, Exercised | shares	(10,335)
Weighted Average Price Per Share, Exercised | $ / shares	$ 54.86
Number of Shares, Forfeited | shares	(1,000)
Weighted Average Price Per Share, Forfeited | $ / shares	$ 2,000
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired | $ / shares
Number of Shares, Outstanding, Ending balance | shares | shares	3,399,085	[1]
Weighted Average Price Per Share, Outstanding, Ending balance | $ / shares	$ 5.51
Number of Shares, Exercisable, Ending balance | shares	3,379,711
Weighted Average Price Per Share, Exercisable, Ending balance | $ / shares	$ 5.55
Weighted average remaining contractual term	2 years 4 months 17 days
Aggregate intrinsic value | $
[1]The 3,399,085

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE (Details) - shares	Mar. 31, 2023		Jun. 30, 2022
Class of Stock [Line Items]
Number of warrants	3,399,085	[1]	105,420
Exercisable	3,379,711
Series A Warrants [Member]
Class of Stock [Line Items]
Number of warrants	9,986
Exercisable	9,986
Series B Warrants [Member]
Class of Stock [Line Items]
Number of warrants	19,375
Exercisable	19,375
Series C Warrants [Member]
Class of Stock [Line Items]
Number of warrants	63,749
Exercisable	44,375
Warrants With No Class Designation [Member]
Class of Stock [Line Items]
Number of warrants	3,305,975
Exercisable	3,305,975
[1]The 3,399,085

SCHEDULE OF SHARE BASED COMPENS

SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY (Details)	9 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance | shares	59
Weighted Average Price Per Share, Outstanding, Beginning balance | $ / shares	$ 4,533
Number of Shares, Granted | shares
Weighted Average Price Per Share, Granted | $ / shares
Number of Shares, Exercised | shares
Weighted Average Price Per Share, Exercised | $ / shares
Number of Shares, Forfeited | shares
Weighted Average Price Per Share, Forfeited | $ / shares
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired | $ / shares
Number of Shares, Outstanding, Ending balance | shares	59
Weighted Average Price Per Share, Outstanding, Ending balance | $ / shares	$ 4,533
Number of Shares, Exercisable, Ending balance | shares	59
Weighted Average Price Per Share, Exercisable, Ending balance | $ / shares	$ 4,533
Weighted average remaining contractual term	6 years 1 month 17 days
Weighted average fair value of options granted during the period	0 years
Aggregate intrinsic value | $

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative)															1 Months Ended	2 Months Ended		3 Months Ended							5 Months Ended	9 Months Ended		12 Months Ended
	Mar. 09, 2023 USD ($) shares	Mar. 08, 2023 USD ($) shares	Mar. 08, 2023 USD ($) shares	Dec. 06, 2022 USD ($) shares	Nov. 16, 2022 USD ($) $ / shares shares	Nov. 03, 2022 USD ($) shares	Nov. 03, 2022 USD ($) shares	Oct. 25, 2022 USD ($) $ / shares shares	Aug. 16, 2022 USD ($) $ / shares shares	Jul. 29, 2022 USD ($) shares	Jul. 29, 2022 shares	Jul. 13, 2022 USD ($) $ / shares shares	Jul. 02, 2022 shares	Nov. 30, 2021 USD ($)	May 31, 2019 USD ($) $ / shares shares	Dec. 27, 2022 USD ($) $ / shares shares	Sep. 14, 2022 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) shares	Sep. 30, 2022 USD ($) shares	Mar. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Sep. 30, 2021 USD ($) shares	Nov. 30, 2022 shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($) $ / shares shares	Sep. 21, 2022 shares	Sep. 20, 2022 shares	May 18, 2022 shares	May 17, 2022 shares	Jun. 30, 2020 USD ($)
Class of Stock [Line Items]
Common Stock, Shares Authorized | shares																		10,000,000,000								10,000,000,000		10,000,000,000	10,000,000,000	3,000,000,000	3,000,000,000	1,000,000,000
Number of preferred stock authorized shares | shares																													1,500,005		1,500,005
Preferred stock, shares authorized | shares																		1,500,005								1,500,005		1,500,005	10,001,500,005		3,001,500,005
Preferred stock, par value | $ / shares																		$ 0.01								$ 0.01		$ 0.01
Shares issued | shares																		1								1		1
Stock issued during period, value																					$ 48,469
Aggregate value																		$ 2,621,298								$ 2,621,298		$ 220,351
Proceeds from issuance of common stock												$ 24,711														24,711
Subscription receivable value																										$ 23,758
Common Stock, Shares, Issued | shares																		2,621,297,786								2,621,297,786		220,350,921
Accrued interest																		$ 12,488								$ 12,488							$ 5,248
Reclassified premium amount for additional paid in capital																		133,000		$ 85,346	133,646	$ 100,840	$ 16,667			351,992	227,150
Debt instrument fair value																		369,110								369,110
Loss on extinguishment debt conversion																		234,622								234,622
Derivative fair value																		223,288								223,288
Gains losses on extinguishment of debt																		(10,724)								32,186
Stock issued during period shares | shares													12,270,958															12,270,958
Stock issued during period value for services																				56,811		89,030
Stock issued during period value for services																										2,408	62,154
Proceeds from the exercise of warrants	$ 175,000			$ 200,000						$ 200,000																$ 375,000	475,000
Number of shares, exercised | shares
Deemed dividend																		0								$ 408,557
Debt discount to be amortized																		$ 54,111				13,647				$ 138,014	24,942
Restricted stock units, value | $ / shares
Common stock per share | $ / shares																		$ 0.001								$ 0.001		$ 0.001
Share based compensation																										$ 0	41,436
Warrants aggregate price																		$ 175,000		100,000	100,000	100,000	100,000	$ 275,000
Share issued value																											448,440
Unvested stock option expense																										$ 0
Stock options granted | shares																										0
2019 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Common stock reserved for future issuances | shares																		234								234
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares															117
Restricted stock units, value | $ / shares															$ 4,250
Fair value granted, shares															$ 497,240
Unrecognized restricted stock units expense																										$ 248,620		$ 248,620
Restricted stock units not yet vested, shares																		$ 248,620								$ 248,620		$ 248,620
Unvested Restricted Stock Units [Member]
Class of Stock [Line Items]
Unvested restricted stock units | shares																		59								59
Series A And C Warrant [Member]
Class of Stock [Line Items]
Issuance of stock | shares																										191,999,040
Series A Warrants [Member]
Class of Stock [Line Items]
Warrants exercise price | $ / shares																		$ 960								$ 960
Warrants exercise price | $ / shares																		200								200
Alternate cashless warrant exercise price | $ / shares																		$ 0.001								$ 0.001
Percentage of exercise price and market price																										70%
Series B Warrants [Member]
Class of Stock [Line Items]
Shares issued | shares		2,500	2,500
Share issued value			$ 100,000
Chief Executive Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares															78
Chief Scientific Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares															39
Convertible Debt [Member]
Class of Stock [Line Items]
Issuance of stock | shares																380,506,070	264,492,661		1,375,598,285
Proceeds from issuance of common stock																$ 165,691	$ 456,939		$ 435,198
Common Stock, Shares, Issued | shares																												7,326,007
Debt Instrument, Convertible, Conversion Price | $ / shares																$ 0.001	$ 0.001		$ 0.0002
Debt instrument face amount																$ 158,500	$ 327,200		$ 290,000
Accrued interest																$ 7,191	$ 22,330		$ 17,985
Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Volatility																		4.74								4.74
Convertible Debt [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Volatility																		267.38								267.38
Settlement and Mutual Release Agreement [Member]
Class of Stock [Line Items]
Convertible notes payable																		$ 122,000								$ 122,000
Gains losses on extinguishment of debt																										11,334
Common Stock [Member]
Class of Stock [Line Items]
Stock issued during period, value																					$ 14,337
Issuance of stock | shares												14,336,712									14,336,712
Share issued price per share | $ / shares												$ 0.002
Reclassified premium amount for additional paid in capital
Stock issued during period shares for services | shares																				79,412,132		2,940,891
Stock issued during period value for services																				$ 79,412		$ 2,941
Number of shares, exercised | shares	4,375			5,000							5,000
Issuance of common stock for exercise of warrants | shares																		3,750		2,500	1,250	1,250	2,500	6,875
Warrants aggregate price																				$ 3	$ 1	$ 1	$ 2	$ 7
Common Stock [Member] | Consultant [Member]
Class of Stock [Line Items]
Share issued price per share | $ / shares					$ 0.00007			$ 0.0009
Stock issued during period shares for services | shares					73,301,020			6,111,112																	73,301,020
Stock issued during period value for services					$ 51,311			$ 5,500
Stock issued during period value for services																										51,311
Warrant [Member]
Class of Stock [Line Items]
Warrants to purchase common stock | shares									1,000,000
Common stock per share | $ / shares									$ 0.01
Warrants expiration date									Aug. 16, 2025
Fair market value of warrants									$ 2,408
Stock valuation price per share | $ / shares									$ 0.0026
Warrant exercise price | $ / shares									$ 0.01
Share based compensation																										2,408
Warrants aggregate price																		$ 150,000
Warrant [Member] | Affiliated Entity [Member]
Class of Stock [Line Items]
Gains losses on extinguishment of debt																										$ 17,499
Warrants to purchase common stock | shares									2,305,000
Common stock per share | $ / shares									$ 0.01
Fair market value of warrants									$ 5,551
Stock valuation price per share | $ / shares									$ 0.0026
Warrant exercise price | $ / shares									$ 0.01
Warrants outstanding payable									$ 23,050
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Volatility									0
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member] | Affiliated Entity [Member]
Class of Stock [Line Items]
Volatility									0
Warrant [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term									3 years
Warrant [Member] | Measurement Input, Expected Term [Member] | Affiliated Entity [Member]
Class of Stock [Line Items]
Maturity term									3 years
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Volatility									3.19
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Affiliated Entity [Member]
Class of Stock [Line Items]
Volatility									3.19
Warrant [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Volatility									236
Warrant [Member] | Measurement Input, Price Volatility [Member] | Affiliated Entity [Member]
Class of Stock [Line Items]
Volatility									236
Series B Warrants [Member]
Class of Stock [Line Items]
Offer from Series B warrants		$ 250,000
Maximum [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term																										10 days
Common Stock Purchase Agreement [Member] | Dutchess [Member]
Class of Stock [Line Items]
Agreement term							36 months							36 months
Lowest trading price														92%
Percentage of average daily trading volume						200%								300%
Aggregate value						$ 250,000	$ 250,000							$ 250,000
Beneficial ownership limitation, percentage						9.99%	9.99%
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock issued during period, value							$ 5,000,000							$ 5,000,000
Underlying Financing Agreements [Member]
Class of Stock [Line Items]
Common stock reserved for future issuances | shares																		5,742,519,659								5,742,519,659
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Debt discount to be amortized																										$ 210,278	$ 66,000
Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Shares issued | shares						75,000,000	75,000,000
Debt instrument face amount						$ 125,000	$ 125,000											$ 125,000								125,000
Accrued interest																		$ 5,103								$ 5,103
Debt discount to be amortized							$ 37,500
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares																		500,000								500,000		500,000
Preferred stock, par value | $ / shares																		$ 0.01								$ 0.01		$ 0.01
Preferred stock shares outstanding | shares																		0								0		500,000
Preferred stock shares issued | shares																		0								0		500,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares																		5								5		5
Preferred stock, par value | $ / shares																		$ 0.01								$ 0.01		$ 0.01
Preferred stock shares outstanding | shares																		1								1		1
Preferred stock shares issued | shares																		1								1		1
Shares issued | shares																		0								0		0
Series B Warrants [Member]
Class of Stock [Line Items]
Number of shares, exercised | shares	4,375			5,000						5,000
Series A Warrants [Member]
Class of Stock [Line Items]
Warrants exercise price | $ / shares																		$ 200								$ 200

SCHEDULE OF RIGHT OF USE ASSET

SCHEDULE OF RIGHT OF USE ASSET (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Office lease	$ 66,201	$ 66,201
Less: accumulated amortization	(21,677)	(3,678)
Right-of-use asset, net	$ 44,524	$ 62,523

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Office lease	$ 66,201	$ 66,201
Reduction of lease liability	(20,077)	(3,277)
Less: office lease, current portion	(21,185)	(20,605)
Long term portion of lease liability	$ 24,939	$ 42,319

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal Year 2023 (remaining)	$ 6,027
Fiscal Year 2024	24,109
Fiscal Year 2025	20,091
Imputed interest	(4,103)
Total operating lease liability	$ 46,124

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)											1 Months Ended																3 Months Ended		5 Months Ended	9 Months Ended		12 Months Ended						21 Months Ended
	Nov. 16, 2022 shares	Oct. 25, 2022 shares	Jul. 27, 2022 USD ($)	Jul. 27, 2022 EUR (€)	May 04, 2022 USD ($)	May 04, 2022 AUD ($)	Oct. 02, 2020 USD ($)	Oct. 02, 2020 EUR (€)	Sep. 13, 2018 USD ($)	Sep. 13, 2018 EUR (€)	Jul. 31, 2023 USD ($)	Jul. 31, 2023 EUR (€)	Mar. 31, 2023 USD ($)	Mar. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Aug. 31, 2022 USD ($)	Aug. 31, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Mar. 31, 2021 USD ($)	Mar. 31, 2021 EUR (€)	Nov. 30, 2020 EUR (€)	Jun. 30, 2012	Dec. 31, 2022 shares	Mar. 31, 2022 shares	Nov. 30, 2022 shares	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Jun. 30, 2019 USD ($)	Jun. 30, 2019 EUR (€)	Mar. 31, 2023 USD ($)	Jun. 30, 2020 USD ($)
Total litigation penalty amount																														$ 30,000
Payment for services																																		$ 24,043	€ 28,493	$ 36,117	€ 31,754
Royalties percentage							2%	2%
unreimbursed lab fees													$ 40,465																	40,465			$ 14,364					$ 40,465
Royalty fees																																	0					0
Accrued expense													12,488																	12,488								12,488	$ 5,248
Payments for Rent																														22,244	$ 19,680
Operating lease right of use asset													$ 44,524																	$ 44,524			$ 62,523					$ 44,524
Incremental borrowing rate					8%	8%
Weighted average remaining lease term													2 years 7 days																	2 years 7 days								2 years 7 days
Accounting Standards Update 2016-02 [Member]
Operating lease right of use asset					$ 66,201
Operating lease liabilities					$ 66,201
Common Stock [Member]
Stock issued during period shares for services | shares																											79,412,132	2,940,891
Common Stock [Member] | Consultant [Member]
Stock issued during period shares for services | shares	73,301,020	6,111,112																											73,301,020
University of Jaen [Member]
Payment for services							$ 30,268	€ 25,837
Royalty Agreement Terms [Member]
Operating leases income statement revenue percentage																										2%
License Agreement Terms [Member]
Operating leases income statement revenue percentage																										5%
1-Year Collaboration Agreement [Member]
Payment for services									$ 59,508	€ 52,000
2-Year Collaboration Agreement [Member]
Payment for services							$ 35,145	€ 30,000	$ 5,775	€ 40,000
Royalty percentage																																		2%	2%
Research Agreement [Member]
Payment for services			$ 53,806	€ 53,200
Research Agreement [Member] | University of Jaen [Member] | Revenue Benchmark [Member] | Revenue from Rights Concentration Risk [Member] | No Customer [Member]
Royalties percentage			2%	2%
Consulting Agreement [Member]
Stock fee percentage													9.90%																	9.90%								9.90%
Accrued expense													$ 83,277																	$ 83,277								$ 83,277
Accrued expense													100,000																	100,000								100,000
Other liabilities													183,277																	183,277								$ 183,277
Consulting Agreement [Member] | Forecast [Member]
Monthly Fee																																$ 50,000
Stock fee percentage																																9.90%
New Three-Year Operating Lease Agreement [Member]
Lessee operating lease term					3 years
Payments for Rent					$ 2,176	$ 3,000
From 2012 through the 2014 [Member]
Total litigation penalty amount																														$ 10,000
Installment 1 [Member] | 2-Year Collaboration Agreement [Member]
Payment for services | €																									€ 5,000
Installment 1 [Member] | Research Agreement [Member]
Payment for services																			$ 18,407	€ 18,200
Installment 2 [Member] | 2-Year Collaboration Agreement [Member]
Payment for services																							$ 5,858	€ 5,000
Installment 2 [Member] | Research Agreement [Member]
Payment for services																	$ 8,091	€ 8,000
Installment 3 [Member] | 2-Year Collaboration Agreement [Member]
Payment for services																					$ 11,715	€ 10,000
Installment 3 [Member] | Research Agreement [Member]
Payment for services															$ 7,080	€ 7,000
Installment 4 [Member] | 2-Year Collaboration Agreement [Member]
Payment for services																	$ 11,715	€ 10,000
Installment 4 [Member] | Research Agreement [Member]
Payment for services													$ 10,114	€ 10,000
Installment 5 [Member] | Research Agreement [Member] | Forecast [Member]
Payment for services											$ 10,114	€ 10,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)																			1 Months Ended	9 Months Ended			12 Months Ended
	Oct. 26, 2022 USD ($)	Oct. 26, 2022 AUD ($)	Aug. 02, 2022 USD ($)	Aug. 02, 2022 AUD ($)	May 04, 2022 USD ($)	May 04, 2022 AUD ($)	Aug. 12, 2021 USD ($) shares	Jul. 13, 2020 AUD ($)	May 14, 2019 USD ($) $ / shares shares	May 14, 2019 AUD ($) shares	Mar. 16, 2018 USD ($)	Mar. 16, 2018 AUD ($)	Feb. 01, 2018 USD ($)	Feb. 01, 2018 AUD ($)	Feb. 25, 2016 USD ($)	Feb. 25, 2016 AUD ($)	Feb. 25, 2015 USD ($)	Feb. 25, 2015 AUD ($)	May 31, 2019 shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2023 AUD ($) shares	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 AUD ($) shares	Jun. 30, 2021 USD ($)	Jun. 30, 2021 AUD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 AUD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2019 AUD ($)	Mar. 31, 2023 AUD ($)	Jun. 30, 2022 AUD ($)
Related Party Transaction [Line Items]
Due to related parties | $																				$ 29,777			$ 30,746
Payments for rent | $																				22,244		$ 19,680
Bonus payable																				$ 33,048	$ 48,387		99,691	$ 144,166
Exercise price | $ / shares
Granted exercise price | $ / shares
Accrued salaries																				$ 56,050			37,341								$ 82,500	$ 54,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments form related party																										$ 221,890	$ 136,606	$ 202,620	$ 64,377	$ 90,000
Bonus payable amount																													137,120	200,000
Remaining bonus amount																				$ 89,002	$ 133,000		$ 125,386	$ 181,324					$ 178,256	$ 260,000
Bonus payable																									$ 166,418	$ 422,610	$ 280,726	$ 407,380
Restricted stock shares of common stock																			78
Nathanielsz Employment Agreement [Member]
Related Party Transaction [Line Items]
Expired date																	Feb. 25, 2019	Feb. 25, 2019
Base salary per month | $																		$ 25,000
Annual salary	$ 414,900	$ 600,000															$ 205,680	$ 300,000
Percentage of pension of monthly salary																				9.50%	9.50%
Percentage of bonus of annual base salary																				200%	200%
Nathanielsz Employment Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Annual salary			$ 414,900	$ 600,000							$ 274,240	$ 400,000
Percentage of bonus of annual base salary																	200%	200%		100%	100%
Nathanielsz Employment Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Annual salary			276,600	400,000							$ 205,680	$ 300,000
Mrs. Nathanielsz [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Bonus payable | $																									$ 316,957
Employment Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																				39	39
Employment Agreement [Member] | Initial Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock									39	39													39	39
Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock unit issuable																				39	39
Services Agreement [Member]
Related Party Transaction [Line Items]
Restricted stock unit issuable																							20	20
Number of restricted stock unit vested, shares																				20	20
Services Agreement [Member] | Initial Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock									20	20
Services Agreement [Member] | Additional Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock									20	20
North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Lessor, Operating lease, term of contract					3 years	3 years
Operating leases rent expense, minimum rentals					$ 2,176	$ 3,000
Former Director [Member]
Related Party Transaction [Line Items]
Loans from related party | $																				$ 29,777			$ 30,746
Due to related parties | $																				49,558			51,171
Nathanielsz [Member] | North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Operating leases, future minimum payments due																				$ 99,872			84,452								$ 149,129	$ 122,129
Mrs. Nathanielsz [Member]
Related Party Transaction [Line Items]
Annual salary													$ 80,904	$ 120,000
Payments form related party																							$ 5,577	$ 7,689
James Nathanielsz [Member]
Related Party Transaction [Line Items]
Payments form related party															$ 3,205	$ 4,481
Mr. Nathanielsz [Member] | Board of Directors [Member]
Related Party Transaction [Line Items]
Officers compensation			$ 96,810	$ 140,000			$ 177,840	$ 240,000	$ 315,376	$ 460,000
Debt conversion, converted instrument, shares issued							5,928,000
Mr. Nathanielsz [Member] | Board of Directors [Member] | AUD Currency [Member]
Related Party Transaction [Line Items]
Bonus granted percentage								60%
Mr. Nathanielsz [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Annual salary									$ 309,313	$ 400,000
Agreement term									3 years	3 years
Option purchase shares									39	39
Exercise price | $ / shares									$ 4,675
Market price									110%	110%
Granted exercise price | $ / shares									$ 4,250
Option term									10 years	10 years
Dr. Kenyon [Member] | Services Agreement [Member]
Related Party Transaction [Line Items]
Annual salary									$ 41,580	$ 54,000
Agreement term									3 years	3 years
Option purchase shares									20	20
Exercise price | $ / shares									$ 4,250
Market price									100%	100%
Option term									10 years	10 years
Dr. Kenyon [Member] | Cancellation Agreement [Member]
Related Party Transaction [Line Items]
Debt conversion, converted instrument, shares issued							3,420,000
Cancellation of accrued salary | $							$ 102,600

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended	21 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Mar. 31, 2023
Concentration Risk [Line Items]
Discounts and debt issuance cost	$ 79,111			$ 66,000
Proceeds from convertible debt	$ 590,250	$ 641,500
Lender [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt		641,500
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt		160,000
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt		235,000
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt		$ 246,500
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	17%	23%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	32%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	25%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Four [Member]
Concentration Risk [Line Items]
Concentration risk percentage	8%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Five [Member]
Concentration Risk [Line Items]
Concentration risk percentage	18%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Two Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage		33%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Three Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage		35%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage			100%	100%
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 101,250
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	189,000
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	150,000
Lender Four [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	50,000
Lender Five [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 100,000

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details) - Convertible Debt [Member]	9 Months Ended
	Mar. 31, 2023
Measurement Input, Price Volatility [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	267.38
Measurement Input, Price Volatility [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	228.29
Measurement Input, Price Volatility [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	256.02
Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	3 days
Measurement Input, Expected Term [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	2 months 19 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	10 days
Measurement Input, Expected Term [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	3 months 10 days
Measurement Input, Risk Free Interest Rate [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	4.74
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	3.13
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	4.42

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities	$ 132,501	$ 151,262
Total	132,501	151,262
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities	132,501	151,262
Total	$ 132,501	$ 151,262

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Balance at Beginning			$ 151,262
Initial fair value of embedded conversion option derivative liability recorded as debt discount			93,668
Reduction of derivative liability upon debt conversion			(223,288)
Change in fair value included in statements of operations	$ 238,367	$ (165,365)	110,859	$ 2,392
Balance at ending	$ 132,501		$ 132,501

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Share price	$ 0.0005
Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Convertible debt	$ 121,500	$ 79,000

SCHEDULE OF REVERSE STOCK SPLIT

SCHEDULE OF REVERSE STOCK SPLIT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Net loss available to Common Stockholders	$ 809,809	$ 700,076	$ 2,321,079	$ 2,198,953
Basic and diluted weighted average shares outstanding	1,924,073,522	66,353,881	1,115,848,071	47,561,123
Basic and diluted net loss per share	$ 0	$ 0.01	$ 0	$ 0.05
Pro Forma [Member]
Net loss available to Common Stockholders	$ 809,809	$ 700,076	$ 2,321,079	$ 2,198,953
Basic and diluted weighted average shares outstanding	1,924,074	66,354	1,115,848	47,561
Basic and diluted net loss per share	$ 0.42	$ 10.55	$ 2.08	$ 46.23

SCHEDULE OF PRO FORMA EFFECT OF

SCHEDULE OF PRO FORMA EFFECT OF REVERSE STOCK SPLIT (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021
Total Assets	$ 143,742			$ 81,651
Total Liabilities	3,085,156			3,105,300
Common Stock	2,621,298			220,351
Common Stock Issuable	4			19,597
Additional Paid In Capital	57,068,986			57,124,982
Subscription Receivable				(23,758)
Accumulated Other Comprehensive Income	1,293,747			1,234,549
Accumulated Deficit	(63,878,972)			(61,557,893)
Treasury Stock	(46,477)			(46,477)
Total Stockholders’ deficit	(2,941,414)	$ (2,915,417)	$ (2,767,535)	(3,023,649)	$ (2,947,420)	$ (2,930,193)	$ (2,306,630)	$ (3,067,573)
Total Liabilities and Basic and Stockholders’ deficit	143,742			81,651
Series A Preferred Stock [Member]
Series A Preferred Stock				5,000
Pro Forma [Member]
Total Assets	143,742			81,651
Total Liabilities	3,085,156			3,105,300
Common Stock	2,621			220
Common Stock Issuable				20
Additional Paid In Capital	59,687,667			57,364,690
Subscription Receivable				(23,758)
Accumulated Other Comprehensive Income	1,293,747			1,234,549
Accumulated Deficit	(63,878,972)			(61,557,893)
Treasury Stock	(46,477)			(46,477)
Total Stockholders’ deficit	(2,941,414)			(3,023,649)
Total Liabilities and Basic and Stockholders’ deficit	143,742			81,651
Pro Forma [Member] | Series A Preferred Stock [Member]
Series A Preferred Stock				5,000
1:1000 adjustment [Member]
Total Assets
Total Liabilities
Common Stock	(2,618,677)			(220,131)
Common Stock Issuable	(4)			(19,577)
Additional Paid In Capital	2,618,681			239,708
Subscription Receivable
Accumulated Other Comprehensive Income
Accumulated Deficit
Treasury Stock
Total Stockholders’ deficit
Total Liabilities and Basic and Stockholders’ deficit
1:1000 adjustment [Member] | Series A Preferred Stock [Member]
Series A Preferred Stock

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		2 Months Ended
	May 01, 2023	May 31, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2020
Subsequent Event [Line Items]
Accrued interest			$ 12,488		$ 5,248
Premiums to additional paid in capital			$ 150,289	$ 313,127
Subsequent Event [Member]
Subsequent Event [Line Items]
Issuance of stock		667,102,561
Conversion price		$ 0.0002
Principal amount		$ 112,750
Accrued interest		6,433
Premiums to additional paid in capital		$ 48,865
Stockholders' Equity, Reverse Stock Split	one-for-one thousand (1:1,000) reverse stock split